Stock Code:3105

WIN SEMICONDUCTORS CORP. AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS

With Independent Auditors' Review Report For the Nine Months Ended September 30, 2023 and 2022

Address: No.69, Keji 7th Rd., Hwaya Technology Park, Guishan Dist., Taoyuan City, Taiwan

Telephone: 886-3-397-5999

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

Table of contents

	Contents	Page
1. Cove	er Page	1
2. Tabl	e of Contents	2
3. Inde	pendent Auditors' Review Report	3
4. Cons	solidated Balance Sheets	4
5. Cons	solidated Statement of Comprehensive Income	5
6. Cons	solidated Statement of Changes in Equity	6
7. Cons	solidated Statement of Cash Flows	7
8. Note	s to the Consolidated Financial Statements	
(1)	Company history	8
(2)	Approval date and procedures of the consolidated financial statements	8
(3)	New standards, amendments and interpretations adopted	8~9
(4)	Summary of material accounting policies	9~12
(5)	Significant accounting assumptions and judgments, and major sources of estimation uncertainty	12
(6)	Explanation of significant accounts	12~55
(7)	Related-party transactions	55~56
(8)	Pledged assets	56
(9)	Commitments and contingencies	57
(10)	Losses due to major disasters	57
(11)	Subsequent events	57
(12)	Other	57~58
(13)	Other disclosures	
	(a) Information on significant transactions	61~65
	(b) Information on investments	65
	(c) Information on investment in mainland China	66
	(d) Information on major shareholders	66
(14)	Segment information	59~60



安侯建業群合會計師事務的 KPMG

台北市110615信義路5段7號68樓(台北101大樓) 68F., TAIPEI 101 TOWER, No. 7, Sec. 5, Xinyi Road, Taipei City 110615, Taiwan (R.O.C.) 電 話 Tel + 886 2 8101 6666 專 真 Fax + 886 2 8101 6667 網 址 Web kpmg.com/tw

Independent Auditors' Review Report

To the Board of Directors of WIN Semiconductors Corp.:

Introduction

We have reviewed the accompanying consolidated balance sheets of WIN Semiconductors Corp. and its subsidiaries as of September 30, 2023 and 2022, and the related consolidated statements of comprehensive income for the three months and nine months ended September 30, 2023 and 2022, as well as the changes in equity and cash flows for the nine months ended September 30, 2023 and 2022, and notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard ("IASs") 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing of the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our reviews and the review report of another auditor (please refer to Other Matter Paragraph), nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of WIN Semiconductors Corp. and its subsidiaries as of September 30, 2023 and 2022, and of its consolidated financial performance for the three months and nine months ended September 30, 2023 and 2022, and its consolidated cash flows for the nine months ended September 30, 2023 and 2022 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.



Other Matter

We did not review the financial statements for the nine months ended September 30, 2022, of certain investments accounted for using the equity method. That financial statements for the nine months ended September 30, 2022 were reviewed by another auditor, whose review report has been furnished to us, and our conclusion, insofar as it relates to the amounts included in these investments, is based solely on the review report of another auditor. The investment accounted for using the equity method amounted to \$9,622,826 thousand, constituting 13.67% of consolidated total assets as of September 30, 2022, the related share of profit of associates and joint ventures accounted for using the equity method amounted to \$53,469 thousand and \$286,544 thousand, respectively, and the related share of other comprehensive income of associates and joint ventures accounted for using the equity method amounted to \$81,504 thousand and \$52,153 thousand, respectively, constituting 13.40%, 17.56%, 20.43% and 3.20% of consolidated total comprehensive income and loss for the three months and nine months ended September 30, 2022, respectively.

The engagement partners on the reviews resulting in this independent auditors' review report are Ya-Ling Chen and Ming-Hung Huang.

KPMG

Taipei, Taiwan (The Republic of China) November 9, 2023

Notes to Readers

The accompanying consolidated financial statements are intended only to present the consolidated statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

Consolidated Balance Sheets

September 30, 2023, December 31, and September 30, 2022

(Expressed in Thousands of New Taiwan Dollars)

		September 30, 2		December 31, 2		September 30, 2		22		September 30, 2		December 31, 20	022	September 30, 2	2022
	Assets	Amount	<u>%</u>	Amount	<u>%</u>	Amount	<u>%</u>		Liabilities and Equity	Amount	<u>%</u>	Amount	<u>%</u>	Amount	<u>%</u>
	Current assets:								Current liabilities:						
1100	Cash and cash equivalents (Note 6(a))	\$ 6,352,259	10	10,379,712	15	10,880,336	15	2100		\$ 21,556	-	-	-	18,805	-
1110	Current financial assets at fair value through profit or loss (Note 6(b))	142,848	-	120,845	-	599,736	1	2120	Total current financial liabilities at fair value through profit or loss (Notes 6(b) and 6(p))	260,587	-	449,261	1	597,050	1
1170	Notes and accounts receivable, net (Notes 6(c) and							2130	Current contract liabilities (Note $6(x)$)	442,779	1	235,309	-	214,889	-
	6(x))	1,206,480	2	916,640	1	1,312,226	2	2170	Notes and accounts payable	1,590,315	3	1,016,716	1	862,882	1
1310	Inventories (Note 6(e))	5,156,864	8	5,420,476	8	5,510,621	8	2200	Other payables (Note 6(y))	2,314,383	4	2,497,109	4	2,505,020	4
1400	Current biological assets (Note 6(f))	172,271	-	93,368	-	54,016	-	2280	Current lease liabilities (Notes 6(q) and 6(ad))	107,361	_	103,570	_	113,276	_
1470	Other current assets (Notes 6(d) and 6(m))	232,536		282,210	1	296,564		2321	Bonds payable, current portion (Notes (p) and 6(ad))	5,272,178	8	-	_	-	_
	Total current assets	13,263,258	_20	17,213,251	25	18,653,499	_26	2322	Long-term borrowings, current portion (Notes (o),						
	Non-current assets:								6(ad) and 8)	3,517,680	5	1,731,147	3	989,227	2
1510	Non-current financial assets at fair value through	4 004 500		4 664 504				2399	Other current liabilities	212,746		213,976		221,614	
	profit or loss (Note 6(b))	1,881,639	3	1,661,503	2	1,740,257	2		Total current liabilities	13,739,585	21	6,247,088	9	5,522,763	8
1517	Non-current financial assets at fair value through other comprehensive income (Note 6(b))	3,068,527	5	1,841,932	3	1,663,060	2		Non-current liabilities:						
1550	Investments accounted for using equity method							2530	Bonds payable (Notes 6(p) and 6(ad))	-	-	10,669,555	16	11,778,373	
	(Note $6(g)$)	10,693,110	16	10,873,014	15	10,351,082	15	2540	Long-term borrowings (Notes 6(o), 6(ad) and 8)	16,398,106		15,870,298	23	16,413,476	
1600	Property, plant and equipment (Notes 6(i) and 8)	32,536,361	49	31,546,006	46	31,683,636	45	2570	Deferred tax liabilities	9,177	-	16,185	-	97,047	
1755	Right-of-use assets (Notes 6(j) and 8)	1,028,737	2	1,099,729	2	1,171,096	2	2580	Non-current lease liabilities (Notes 6(q) and 6(ad))	865,224	1	924,832	1	976,907	2
1760	Investment property (Note 6(k))	1,044,644	2	1,048,632	1	1,049,961	2	2600	Other non-current liabilities (Notes 6(s), 6(ad) and 7	212,104		210,711		232,810	
1780	Intangible assets (Note 6(1))	550,323	1	562,305	1	585,701	1		Total non-current liabilities	17,484,611	<u>26</u>	27,691,581	40	29,498,613	42
1830	Non-current biological assets (Note 6(f))	235,860	-	273,554	-	318,468	-		Total liabilities	31,224,196	<u>47</u>	33,938,669	49	35,021,376	_50
1840	Deferred tax assets	917,917	1	756,114	1	682,412	1		Equity (Notes 6(b), 6(g), 6(h), 6(p), 6(u) and 6(v)):						
1915	Prepayments for business facilities	383,241	-	1,765,808	3	1,943,197	3	3110	Ordinary shares	4,239,404	6	4,239,404	6	4,239,404	6
1990	Other non-current assets (Notes 6(m) and 8)	477,567	1	486,365	1	555,328	1	3200	Capital surplus	9,966,566	15	9,964,088	14	9,966,730	14
	Total non-current assets	52,817,926	80	51,914,962	75	51,744,198	74	3300	Retained earnings	16,826,859	26	18,351,411	27	18,465,736	26
								3400	Other equity interests	2,290,496	4	773,633	1	735,589	1
									Total equity attributable to owners of parent	33,323,325	51	33,328,536	48	33,407,459	47
								36XX	Non-controlling interests	1,533,663	2	1,861,008	3	1,968,862	3
									Total equity	34,856,988	53	35,189,544	51	35,376,321	_50
	Total assets	\$ 66,081,184	<u>100</u>	69,128,213	<u>100</u>	70,397,697	<u>100</u>		Total liabilities and equity	\$ <u>66,081,184</u>	<u>100</u>	69,128,213	<u>100</u>	70,397,697	<u>100</u>

Consolidated Statement of Comprehensive Income

For the three months and nine months ended September 30, 2023 and 2022

(Expressed in Thousands of New Taiwan Dollars, Except for Earnings Per Common Share)

		For the three months ended Se			r 30		months ended Septemb		r 30
		2023	0/	2022	0/	2023		2022	
4000		Amount	<u>%</u>	Amount	<u>%</u>	Amount	<u>%</u>	Amount	<u>%</u>
4000	Operating revenue (Notes $6(b)$, $6(g)$ and $6(x)$)	\$ 4,165,010	100	3,908,742	100	10,968,462	100	14,803,060	100
5000	Operating costs (Notes 6(e), 6(f), 6(g), 6(i), 6(j), 6(q), 6(s), 6(v), 6(y), 7 and 12)	(3,245,768)	<u>(78</u>)	(3,284,408)	<u>(84</u>)	(8,932,179)	<u>(81</u>)	(10,863,858)	<u>(73</u>)
	Gross profit from operating	919,242	22	624,334	16	2,036,283	19	3,939,202	27
6100	Operating expenses (Notes $6(c)$, $6(i)$, $6(j)$, $6(q)$, $6(s)$, $6(v)$, $6(y)$, 7 and 12):	(101.500)	(2)	(00.050)	(2)	(216.00=)	(2)	(250 500)	(2)
6100	Selling expenses	(101,508)	(2)	(89,053)	(2)	(316,997)	(3)	(270,709)	(2)
6200	Administrative expenses	(307,501)	(7)	(286,570)	(7)	(963,510)	(9)	(1,004,892)	(7)
6300	Research and development expenses	(440,155)	(11)	(448,447)	(12)	(1,450,940)	(13)	(1,199,886)	(8)
6450	Gains (losses) on expected credit impairment	<u>(6</u>)		(705)		221		<u>(704</u>)	
	Total operating expenses	(849,170)	<u>(20</u>)	(824,775)	<u>(21</u>)	(2,731,226)	<u>(25</u>)	(2,476,191)	<u>(17</u>)
	Net operating income (loss)	70,072	2	(200,441)	<u>(5</u>)	<u>(694,943</u>)	<u>(6</u>)	1,463,011	<u>10</u>
	Non-operating income and expenses (Notes 6(b), 6(g), 6(i), 6(p), 6(q), 6(z), 6(ad) and 7):								
7100	Interest income	29,394	1	21,541	1	156,720	1	42,905	-
7010	Other income	26,401	1	35,948	1	63,571	1	207,099	1
7020	Other gains and losses	(24,837)	(1)	473,629	12	1,894	-	278,102	2
7050	Finance costs	(173,710)	(5)	(84,708)	(2)	(483,675)	(4)	(246,561)	(1)
7060	Share of profit (loss) of associates and joint ventures accounted for using equity								
	method, net	28,484	1	53,359	1	(5,063)		214,210	1
	Total non-operating income and expenses	(114,268)	<u>(3</u>)	499,769	13	(266,553)	<u>(2</u>)	495,755	3
7900	Profit (loss) before tax	(44,196)	(1)	299,328	8	(961,496)	(8)	1,958,766	13
7950	Tax benefit (expense) (Note 6(t))	(36,862)	<u>(1</u>)	(54,594)	<u>(2</u>)	125,670	1	(383,803)	<u>(2</u>)
	Profit (loss)	(81,058)	<u>(2</u>)	244,734	6	(835,826)	<u>(7</u>)	1,574,963	11
8300	Other comprehensive income:								
8310	Components of other comprehensive income that will not be reclassified to profit or loss (Notes 6(g) and 6(u))								
8316	Unrealized gains (losses) from investments in equity instruments measured at fair								
	value through other comprehensive income	335,083	8	(98,567)	(2)	1,240,559	11	(494,755)	(3)
8320	Share of other comprehensive income of associates and joint ventures accounted								
	for using equity method that will not be reclassified to profit or loss	4,191	-	962	-	4,389	-	1,399	-
8349	Income tax related to components of other comprehensive income that will not be								
	reclassified to profit or loss								
	Total components of other comprehensive income (loss) that will not be								
	reclassified to profit or loss	339,274	8	<u>(97,605</u>)	<u>(2</u>)	1,244,948	<u>11</u>	(493,356)	<u>(3</u>)
8360	Components of other comprehensive income that will be reclassified to profit or loss (Notes 6(g) and 6(u))								
8361	Exchange differences on translation of foreign financial statements	348,294	8	211,031	5	251,794	2	568,472	3
8370	Share of other comprehensive income of associates and joint ventures accounted								
	for using equity method that will be reclassified to profit or loss	183,104	5	40,794	1	54,019	1	(18,600)	-
8399	Income tax related to components of other comprehensive income that will be reclassified to profit or loss	-	_	-	_	_	_	_	_
	Total components of other comprehensive income (loss) that will be			_				_	
	reclassified to profit or loss	531,398	13	251,825	6	305,813	3	549,872	3
8300	Other comprehensive income, net	870,672	21	154,220	4	1,550,761	14	56,516	
8500	Total comprehensive income	\$ 789,614	19	398,954	10	714,935	7	1,631,479	11
	Profit (loss) attributable to:								
8610	Profit (loss) attributable to owners of parent	\$ 34,033	1	351,809	9	(464,701)	(4)	1,878,060	13
8620	Profit (loss) attributable to non-controlling interests	(115,091)	(3)	(107,075)	(3)	(371,125)	(3)	(303,097)	(2)
		\$ (81,058)	(2)	244,734	6	(835,826)	$\overline{(7)}$	1,574,963	11
	Comprehensive income attributable to:								
8710		\$ 845,622	20	482,093	12	1,052,162	10	1,857,817	13
8720	Comprehensive income, attributable to non-controlling interests	(56,008)	(1)	(83,139)	(2)	(337,227)	(3)	(226,338)	(2)
	1, mais more to non commonly moreon	\$ 789,614	19	398,954	$\frac{(2)}{10}$	714,935	7	1,631,479	11
	Earnings per common share (expressed in New Taiwan dollars) (Note 6(w))	707,014		570,75 1		711,700	<u> </u>	1,001,17	
9750	Basic earnings per share	\$0.08		0.83		(1.10)		4.43	
9850	Diluted earnings per share	\$ 0.08	=	0.35		$\frac{(1.10)}{(1.18)}$		4.41	
7050	Diraced carmings per snare	Ψ	=	0.43		(1.10)			

Consolidated Statement of Changes in Equity

For the nine months ended September 30, 2023 and 2022

(Expressed in Thousands of New Taiwan Dollars)

				Eq	uity attributab	le to owners of p	parent					
							Other equit	y interests				
							Unrealized					
							gains					
				Retained earnings		Exchange	(losses) on financial assets	Other				
				Retained earnings		differences on	measured at	unearned				
						translation of	fair value	compensation		Total equity		
					Total	foreign	through other	for restricted		attributable to		
	Ordinary	Capital		Unappropriated	retained	financial	comprehensive	shares of	Total other	owners of	Non-controlling	
	shares	surplus		retained earnings	earnings	statements	income		equity interests	parent	interests	Total equity
Balance at January 1, 2022	\$ <u>4,239,764</u>	9,969,914	3,172,722	16,787,543	19,960,265	(269,409)	1,044,071	(6,597)	768,065	34,938,008	2,183,988	37,121,996
Appropriation and distribution of retained earnings:												
Legal reserve appropriated	-	-	719,966	, , ,	-	-	-	-	-	-	-	-
Cash dividends of ordinary shares				(3,391,811)	(3,391,811)					(3,391,811)		(3,391,811)
			719,966	(4,111,777)	(3,391,811)					(3,391,811)		(3,391,811)
Profit (losses) for the nine months ended September 30, 2022	-	-	-	1,878,060	1,878,060	-	-	-	-	1,878,060	(303,097)	1,574,963
Other comprehensive income(loss) for the nine months ended September 30,												
2022						473,113	(493,356)		(20,243)			56,516
Total comprehensive income for the nine months ended September 30, 2022				1,878,060	1,878,060	473,113	(493,356)		(20,243)	1,857,817	(226,338)	1,631,479
Compensation cost arising from restricted shares of employees	-	-	-	-	-	-	-	39	39	39	-	39
Purchase and retirement of restricted shares of stock for employees	(360)	(6,198)) -	-	-	-	-	6,558	6,558	-	-	-
Changes in equity of associates accounted for using equity method	-	3,014	-	392	392	-	-	-	-	3,406	-	3,406
Stock option compensation cost of subsidiary	-	-	-	-	-	-	-	-	-	-	11,212	11,212
Disposal of investments in equity instruments designated at fair value through							(40.000)					
other comprehensive income				18,830	18,830		(18,830)		(18,830)			
Balance at September 30, 2022	\$ <u>4,239,404</u>	9,966,730	3,892,688	14,573,048	18,465,736	203,704	531,885		735,589	33,407,459	1,968,862	35,376,321
Balance at January 1, 2023	\$ 4,239,404	9,964,088	3,892,688	14,458,723	18,351,411	61,004	712,629		773,633	33,328,536	1,861,008	35,189,544
Appropriation and distribution of retained earnings:												
Legal reserve appropriated	-	-	178,296			-	-	-	-	-	-	-
Cash dividends of ordinary shares				(1,059,851)	(1,059,851)					(1,059,851)		(1,059,851)
			178,296	(1,238,147)	(1,059,851)					(1,059,851)		(1,059,851)
Losses for the nine months ended September 30, 2023	-	-	-	(464,701)	(464,701)	-	-	-	-	(464,701)	(371,125)	(835,826)
Other comprehensive income for the nine months ended September 30, 2023						271,911	1,244,952		1,516,863	1,516,863	33,898	1,550,761
Total comprehensive income for the nine months ended September 30, 2023				(464,701)	(464,701)	271,911	1,244,952		1,516,863	1,052,162	(337,227)	714,935
Changes in equity of associates accounted for using equity method	-	2,478	-	-	-	-	-	-	-	2,478	-	2,478
Stock option compensation cost of subsidiary											9,882	9,882
Balance at September 30, 2023	\$ <u>4,239,404</u>	9,966,566	4,070,984	12,755,875	16,826,859	332,915	1,957,581	<u> </u>	2,290,496	33,323,325	1,533,663	34,856,988

Consolidated Statement of Cash Flows

For the nine months ended September 30, 2023 and 2022

(Expressed in Thousands of New Taiwan Dollars)

	For	the nine months ended	ded September 30	
Cash flows from (used in) operating activities:		2023	<u> </u>	
(Loss) profit before tax	\$	(961,496)	1,958,766	
Adjustments: Adjustments to reconcile profit (loss):				
Depreciation expense		3,430,831	3,146,741	
Amortization expense		88,945	107,305	
Loss on (reversal of) expected credit impairment		(221)	704	
Net (gains) losses on financial assets or liabilities at fair value through profit or loss		(162,152) 483,675	715,883 246,561	
Interest expense Interest income		(156,720)	(42,905)	
Dividend income		(65,279)	(205,733)	
Share-based payments		9,882	11,251	
Share of loss (profit) of associates and joint ventures accounted for using equity method		15,213	(259,255)	
Losses (gains) on disposal of property, plant and equipment Prepayments for business facilities transferred to expenses		18,694 1,008	(36,001) 48	
Property, plant and equipment transferred to expenses		2,865	-	
Changes in biological assets at fair value		2,432	(4,244)	
Unrealized foreign exchange losses		327,664	614,269	
Gains on repurchases of bonds payable		(712,679)	(360,101)	
(Gains) losses on lease modification Total adjustments to reconcile profit (loss)		(24) 3,284,134	26,426 3,960,949	
Changes in operating assets and liabilities:		3,264,134	3,900,949	
Changes in operating assets:				
Increase in financial assets at fair value through profit or loss		(9,840)	(543,880)	
(Increase) decrease in notes and accounts receivable		(289,620)	1,404,629	
Decrease in inventories (Increase) decrease in biological assets		263,149 (119,211)	998,570 98,731	
Decrease in other current assets		20,665	129,435	
Total changes in operating assets		(134,857)	2,087,485	
Changes in operating liabilities:				
Increase (decrease) in contract liabilities		207,470	(138,268)	
Increase (decrease) in notes and accounts payable Decrease in other payables		573,599 (225,924)	(1,299,943) (877,637)	
(Decrease) increase in other current liabilities		(1,230)	44,709	
Increase in other non-current liabilities		522	349	
Total changes in operating liabilities		554,437	(2,270,790)	
Total changes in operating assets and liabilities		419,580	(183,305)	
Cash flows generated from operations Dividends received		2,742,218 32,226	5,736,410 27,466	
Income taxes paid		(84,270)	(1,375,915)	
Net cash flows from operating activities		2,690,174	4,387,961	
Cash flows from (used in) investing activities:		(-)		
Acquisition of financial assets at fair value through other comprehensive income		(720)	10.744	
Proceeds from disposal of financial assets at fair value through other comprehensive income Proceeds from capital reduction of financial assets at fair value through other comprehensive income		18,000	19,744 17,667	
Acquisition of financial assets at fair value through profit or loss		(61,351)	(64,437)	
Proceeds from disposal of financial assets at fair value through profit or loss		-	9,969	
Proceeds from capital reduction of financial assets at fair value through profit or loss		21,821	8,719	
Acquisition of investments accounted for using equity method		(14,498)	- (4 569 222)	
Acquisition of property, plant and equipment Proceeds from disposal of property, plant and equipment		(2,856,325) 5,782	(4,568,332) 80,743	
Acquisition of intangible assets		(80,393)	(63,704)	
Acquisition of right-of-use assets		(220)	-	
Increase in other non-current assets		- 0.562	(235,453)	
Decrease in other non-current assets		8,763	(1,639,575)	
Increase in prepayments for business facilities Interest received		(100,358) 171,220	41,743	
Dividends received		292,077	576,478	
Net cash flows used in investing activities		(2,596,202)	(5,816,438)	
Cash flows from (used in) financing activities:			40.005	
Increase in short-term loans Proceeds from long term debt		21,556 3,444,764	18,805 5,659,996	
Proceeds from long-term debt Repayments of long-term debt		(1,579,227)	(5,123,113)	
Repayments of lease liabilities		(69,209)	(85,272)	
Increase (decrease) in other non-current liabilities		871	(10,963)	
Cash dividends paid		(1,059,851)	(3,391,811)	
Interest paid		(252,833)	(84,774)	
Repurchases of bonds payable Net cash flows used in financing activities		(4,881,706) (4,375,635)	(1,277,473) (4,294,605)	
Effect of exchange rate changes on cash and cash equivalents		254,210	271,659	
Net decrease in cash and cash equivalents		(4,027,453)	(5,451,423)	
Cash and cash equivalents at beginning of period		10,379,712	16,331,759	
Cash and cash equivalents at end of period	\$	6,352,259	10,880,336	

Notes to the Consolidated Financial Statements

September 30, 2023 and 2022

(Expressed in Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(1) Company history:

WIN Semiconductors Corp. (the "Company") was incorporated on October 16, 1999 as a company limited by shares and registered under the Ministry of Economic Affairs, R.O.C. The address of the Company's registered office is No. 69, Keji 7th Rd., Hwaya Technology Park, Guishan Dist., Taoyuan City, Taiwan.

The main operations of the Company and its subsidiaries (together referred to as "the Group") are as follows:

- (a) Researching, developing, manufacturing, and selling of GaAs wafers.
- (b) Developing hog farming technology and trading.
- (c) Researching, manufacturing and selling of high-density gene chips, biochip optical readers, microelectrophoresis analyzers and diagnostic tool for endometrial cancer.

(2) Approval date and procedures of the consolidated financial statements:

The consolidated financial statements for the nine Months ended September 30, 2023 and 2022 were authorized for issuance by the board of directors on November 9, 2023.

(3) New standards, amendments and interpretations adopted:

(a) The impact of the International Financial Reporting Standards ("IFRSs") endorsed by the Financial Supervisory Commission, R.O.C. ("FSC") which have already been adopted.

The Group has initially adopted the following new amendments, which do not have a significant impact on its consolidated financial statements, from January 1, 2023:

- Amendments to IAS 1 "Disclosure of Accounting Policies"
- Amendments to IAS 8 "Definition of Accounting Estimates"
- Amendments to IAS 12 "Deferred Tax related to Assets and Liabilities arising from a Single Transaction"

The Group has initially adopted the new amendment, which do not have a significant impact on its consolidated financial statements, from May 23, 2023:

• Amendments to IAS 12 "International Tax Reform—Pillar Two Model Rules"

(b) The impact of IFRS issued by the FSC but not yet effective

The Group assesses that the adoption of the following new amendments, effective for annual period beginning on January 1, 2024, would not have a significant impact on its consolidated financial statements:

- Amendments to IAS 1 "Classification of Liabilities as Current or Non-current"
- Amendments to IAS 1 "Non-current Liabilities with Covenants"
- Amendments to IAS 7 and IFRS 7 "Supplier Finance Arrangements"
- Amendments to IFRS 16 "Lease Liability in a Sale and Leaseback"

(c) The impact of IFRS issued by IASB but not yet endorsed by the FSC

The Group does not expect the following new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its consolidated financial statements:

- Amendments to IFRS 10 and IAS 28 "Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture"
- IFRS 17 "Insurance Contracts" and its amendments
- Amendments to IFRS 17 "Initial Application of IFRS 17 and IFRS 9 Comparative Information"
- Amendments to IAS21 "Lack of Exchangeability"

(4) Summary of material accounting policies:

Except the following accounting policies mentioned below, the material accounting policies adopted in the consolidated financial statements are the same as those in the consolidated financial statement for the year ended December 31, 2022. For the related information, please refer to Note 4 of the consolidated financial statements for the year ended December 31, 2022.

(a) Statement of compliance

These consolidated financial statements have been prepared in accordance with the preparation and guidelines of IAS 34 "Interim Financial Reporting" which are endorsed by FSC, and do not include all of the information required by the Regulations and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed by the FSC (hereinafter referred to IFRS endorsed by the FSC) for a complete set of the annual consolidated financial statements.

(b) Basis of consolidation

(i) List of subsidiaries in the consolidated financial statements:

				Shareholding		
			September 30,	December 31,	September 30,	
Name of investor	Name of subsidiary	Principal activity	2023	2022	2022	Remark
The Company	WIN SEMI. USA, INC.	Marketing	100.00 %	100.00 %	100.00 %	
The Company	Win Semiconductors Cayman Islands Co., Ltd. (abbrev. Win Cayman)	Investment activities	100.00 %	100.00 %	100.00 %	
The Company	WIN Venture Capital Corp. (abbrev. WVC)	Investment activities	100.00 %	100.00 %	100.00 %	
The Company	Phalanx Biotech Group, Inc. (abbrev. PBL)	Researching, manufacturing and selling of high-density gene chips and testing service	73.67 %	73.67 %	73.67 %	
The Company	WIN Earn Investment Corp.	Investment activities	100.00 %	100.00 %	100.00 %	
The Company	WIN Chance Investment Corp.	Investment activities	100.00 %	100.00 %	100.00 %	
WVC	Phalanx Biotech Group, Inc.	Researching, manufacturing and selling of high-density gene chips and testing service	1.54 %	1.54 %	1.54 %	
Win Cayman	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. (abbrev. Chainwin Cayman)	Investment activities	81.23 %	81.23 %	81.23 %	
Chainwin Cayman	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Chance Agriculture Development Co., Ltd. (abbrev. Jiangsu Win Chance)	Developing hog farming technology and trading	-	100.00 %	100.00 %	(Note 1)
Chainwin Cayman	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd. (abbrev. Jiangsu Chainwin)	Farm feed development and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Merit Runfu Agriculture Development Co., Ltd.	Developing hog farming technology and trading	-	-	100.00 %	(Note 1)
Chainwin Cayman	Jiangsu Win Yield Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	i-Chainwin Technology (Cayman Islands) Co., Ltd.	Investment activities	-	100.00 %	100.00 %	(Note 2)
Chainwin Cayman	Win Lux Biotech (Cayman Islands) Co., Ltd.	Investment activities	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Shine Agriculture Development Co., Ltd.	Logistics management service	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	i-Chainwin Technology Co., Ltd.	Information software services	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Win Lux Biotech Co., Ltd.	Biotechnology service and pharmaceutical testing	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Boutique Agriculture Development Co., Ltd.	Developing hog farming technology and trading	-	-	100.00 %	(Note 1)
Chainwin Cayman	Jiangsu Win Sunlight Agriculture Development Co., Ltd.	Developing hog farming technology and trading	-	100.00 %	100.00 %	(Note 1)
Chainwin Cayman	Jiangsu Win Honor Management Technology Co., Ltd.	Logistics management service	-	-	100.00 %	(Note 1)
Chainwin Cayman	Jiangsu Win Fortune Agriculture Development Co., Ltd.	Developing hog farming technology and trading	-	100.00 %	100.00 %	(Note 1)
Chainwin Cayman	Chainwin (Huaian) AloT Co., Ltd.	Information software services	-	100.00 %	100.00 %	(Note 1)
Chainwin Cayman	Jiangsu Win Advane Bio-Assay Co., Ltd.	Biotechnology testing service	-	100.00 %	100.00 %	(Note 1)
Chainwin Cayman	Jiangsu Win Lux Biotech Co., Ltd.	Biotech research and development and bioassay	100.00 %	100.00 %	100.00 %	

			Shareholding			
			September 30,	December 31,	September 30,	
Name of investor	Name of subsidiary	Principal activity	2023	2022	2022	Remark
Jiangsu Win Chance	Jiangsu Win Wonder Agriculture Development Co., Ltd.	Developing farming technology and trading	100.00 %	100.00 %	100.00 %	
Jiangsu Win Chance	Jiangsu Merit Runfu Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	-	(Note 1)
Jiangsu Chainwin	Jiangsu Win Boutique Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	-	(Note 1)
Jiangsu Chainwin	Jiangsu Win Honor Management Technology Co., Ltd.	Logistics management service	100.00 %	100.00 %	-	(Note 1)
Jiangsu Chainwin	Chainwin (Huaian) AloT Co., Ltd.	Information software services	100.00 %	-	-	(Note 1)
Jiangsu Chainwin	Jiangsu Win Sunlight Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	-	-	(Note 1)
Jiangsu Chainwin	Jiangsu Win Chance Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	-	-	(Note 1)
Jiangsu Chainwin	Jiangsu Win Fortune Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	-	-	(Note 1)
Jiangsu Chainwin	Jiangsu Win Advane Bio-Assay Co., Ltd.	Biotechnology testing service	100.00 %	-	-	(Note 1)
PBL	PhalanxBio, Inc.	Selling of high-density gene chips and testing service	100.00 %	100.00 %	100.00 %	
PBL	Phalanx Biotech Limited. (abbrev. PBL (HK))	Investment activities	100.00 %	100.00 %	100.00 %	
PBL	Guzip Biomarkers Corporation	Developing and selling of diagnostic tool for endometrial cancer	100.00 %	100.00 %	100.00 %	
PBL (HK)	Onearray Biotech (Kunshan) Co., Ltd.	Selling of high-density gene chips and testing service	100.00 %	100.00 %	100.00 %	

Note 1: Changes in organizational structure.

Note 2: The liquidation process is completed in the $1^{\rm st}$ quarter of 2023.

Note 3: The aforementioned subsidiaries were recognized based on the reviewed financial statements by the certified public accountant.

(ii) List of subsidiaries which are not included in the consolidated financial statements: None.

(c) Government grants

The Group recognizes an unconditional government grant related to property, plant and equipment, research and development plan in profit or loss as other income when the grant becomes receivable. Grants that compensate the Group for expenses or losses incurred are recognized in profit or loss on a systematic basis in the periods in which the expenses or losses are recognized.

(d) Employee benefits

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year, adjusted for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-time events.

(e) Income taxes

The income tax expenses have been evaluated and disclosed in accordance with paragraph B12 of IAS 34 "Interim Financial Reporting."

Income tax expenses for the period are measured by multiplying together the pre-tax income for the interim reporting period and the management's best estimate of effective annual tax rate. This should be recognized fully as tax expense for the current period.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty:

The preparation of the consolidated financial statements in conformity with the Regulations and IFRSs (in accordance with IAS 34 "Interim Financial Reporting" and endorsed by the FSC) requires management to make judgments, estimates and assumptions that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Significant accounting estimates and assumptions made by the management may differ from the actual results and are continually evaluated and adjusted based on historical experience and other factors. The Group has considered the economic implications of climate change on critical accounting estimates and will continue evaluating the impact on its financial position and financial performance.

The preparation of the consolidated financial statements, estimates and underlying assumptions are reviewed on an ongoing basis which are in conformity with the consolidated financial statements for the year ended December 31, 2022. For the related information, please refer to Note 5 of the consolidated financial statements for the year ended December 31, 2022.

(6) Explanation of significant accounts:

Except for the following disclosure, the significant account disclosure in the consolidated financial statements for the nine months ended September 30, 2023, which compare with the consolidated financial statements for the year ended December 31, 2022, was not changed significantly. For the related information, please refer to Note 6 of the consolidated financial statements for the year ended December 31, 2022.

(a) Cash and cash equivalents

	Sept	tember 30, 2023	December 31, 2022	September 30, 2022
Cash on hand	\$	230	230	260
Cash in bank		6,169,249	7,022,482	9,715,576
Time deposits		182,780	3,357,000	1,164,500
	\$	6,352,259	10,379,712	10,880,336

Please refer to Note 6(aa) for the currency risk and sensitivity analysis of the financial assets and liabilities of the Group.

(b) Financial instruments

(i) Financial assets and liabilities at fair value through profit or loss:

	Se	eptember 30, 2023	December 31, 2022	September 30, 2022
Mandatorily measured at financial assets at fair value through profit or loss:				
Non-derivative financial assets				
Publicly traded stocks (Note 1)	\$	460,509	301,109	290,366
Money market funds		136,649	111,296	587,762
Private fund (Note 1)(Note 2)		1,427,329	1,369,943	1,461,865
Total	\$	2,024,487	1,782,348	2,339,993
Current	\$	142,848	120,845	599,736
Non-current		1,881,639	1,661,503	1,740,257
	\$	2,024,487	1,782,348	2,339,993

Note 1: As of September 30, 2023, December 31 and September 30, 2022, parts of the private fund and publicly traded stocks were during the lock-up period.

Note 2: The 32.44% shares of the Group in NFC Fund II L.P. is deemed as mutual fund. Since the Group is only a limited partner of the fund, it cannot be allowed any representative to take part in the decision making of the policy of NFC Fund II L.P. As a result, the Group has no significant influence over the company.

	Sep	otember 30, 2023	December 31, 2022	September 30, 2022
Mandatorily measured at current financial liabilities at fair value through profit or loss				
Convertible bonds with embedded derivatives	\$	260,587	449,261	597,050

The derivative financial instruments arose from the issuance of overseas convertible bonds of the Group disclosed in Note 6(p).

Refer to Note 6(z) for the amount of re-measurement at fair value recognized in profit or loss.

(ii) Non-current financial assets at fair value through other comprehensive income (FVOCI):

	September 30,		December 31,	September 30,
	2023		2022	2022
Stocks listed on domestic markets	\$	652,770	73,796	69,299
Stocks listed on US markets		2,010,211	1,287,816	1,057,299
Non-public stocks		405,546	480,320	536,462
	\$	3,068,527	1,841,932	1,663,060

The Group decided to hold these equity instruments, which are not held for trading, at fair value through other comprehensive income.

For the nine months ended September 30, 2023, there were no disposals of equity investments at fair value through other comprehensive income, and the gains and losses accumulated in other equity were not transferred to retained earnings during the period.

For the nine months ended September 30, 2022, due to the redemption of preferred shares, the Group disposed the financial assets at fair value through other comprehensive income, with a fair value of \$19,744 thousand; upon derecognition, the gains on disposal, accumulated in other equity, amounting to \$18,830 thousand was transferred to retained earnings.

For the three months and nine months ended September 30, 2023 and 2022, the Group received dividend income \$14,118 thousand, \$30,340 thousand, \$36,987 thousand and \$50,048 thousand, respectively, of the equity investment designated at fair value though other comprehensive income.

(iii) Sensitivity analysis in the equity price risk:

If the equity price changes, the impact to comprehensive income, using the sensitivity analysis based on the same variables except for the price index for both periods, will be as follows:

	For the nine mo September 3		For the nine months ended September 30, 2022			
Prices of securities at the reporting date	After-tax other comprehensive income	After-tax profit (loss)	After-tax other comprehensive income	After-tax profit (loss)		
Increasing 3%	\$ 92,056	13,815	49,892	8,711		
Decreasing 3%	\$(92,056)	(13,815)	(49,892)	(8,711)		

(iv) As of September 30, 2023, December 31 and September 30, 2022, the financial assets were not pledged. For information on the Group's credit risk, currency risk, and fair value information was disclosed in Note 6(aa).

(c) Notes and accounts receivable, net

	Sep	September 30, 2023		September 30, 2022	
Notes receivable	\$	1,071	1,310	830	
Accounts receivable		1,206,174	916,315	1,312,997	
Less: loss allowance		(765)	(985)	(1,601)	
	\$	1,206,480	916,640	1,312,226	

The Group applies the simplified approach to provide for its loss allowance used for expected credit losses, which permit the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, notes and accounts receivable have been grouped based on shared credit risk characteristics and days past due, as well as incorporate forward looking information.

The loss allowance was determined as follows:

(i) The segment of foundry and agriculture technology:

	September 30, 2023			
		oss carrying amount	Weighted- average expected loss rate	Lifetime expected credit loss allowance
Not past due	\$	1,139,045	0%	-
Past due 1~60 days		59,615	0%	-
Past due 61~120 days		1,407	0%	-
Past due 121~180 days		-	8.82%~23.75%	-
Past due more than 181 days		-	100%	
	\$	1,200,067		<u> </u>
]	December 31, 2022	
		oss carrying amount	Weighted- average expected loss rate	Lifetime expected credit loss allowance
Not past due	\$	857,657	0%	
Past due 1~60 days		49,028	0%	-
Past due 61~120 days		1,165	0%	-
Past due 121~180 days		2,636	0%~3.33%	-
Past due more than 181 days		-	100%	
	\$	910,486		

	September 30, 2022			
			Weighted-	Lifetime
	Gr	oss carrying amount	average expected loss rate	expected credit loss allowance
Not past due	\$	1,168,468	0%	-
Past due 1~60 days		131,551	0%	-
Past due 61~120 days		4,438	0%	-
Past due 121~180 days		-	0%~1.67%	-
Past due more than 181 days		699	100%	699
	\$	1,305,156		699

(ii) The segment of gene chip testing service:

	September 30, 2023			
	G	ross carrying amount	Weighted- average expected loss rate	Lifetime expected credit loss allowance
Not past due	\$	5,445	0%~2.64%	10
Past due 1~60 days		885	0%~4.80%	-
Past due 61~120 days		75	0%~7.24%	-
Past due 121~180 days		20	0%~36.11%	2
Past due more than 181 days	_	753	100%	753
	\$	7,178		<u>765</u>
]	December 31, 2022	
	G	ross carrying amount	December 31, 2022 Weighted- average expected loss rate	Lifetime expected credit loss allowance
Not past due	G:	ross carrying	Weighted- average expected	Lifetime expected credit
Not past due Past due 1~60 days		ross carrying amount	Weighted- average expected loss rate	Lifetime expected credit loss allowance
		ross carrying amount 5,177	Weighted- average expected loss rate 0%~0.35%	Lifetime expected credit loss allowance 100
Past due 1~60 days		ross carrying amount 5,177	Weighted- average expected loss rate 0%~0.35% 0%~7.26%	Lifetime expected credit loss allowance 100
Past due 1~60 days Past due 61~120 days		ross carrying amount 5,177	Weighted- average expected loss rate 0%~0.35% 0%~7.26% 0%~19.44%	Lifetime expected credit loss allowance 100

September 30, 2022 Weighted-Lifetime Gross carrying average expected expected credit loss allowance amount loss rate Not past due 6,995 0%~1.14% 6 Past due 1~60 days 814 0%~13.89% 97 Past due 61~120 days 26 0%~25% 6 Past due 121~180 days 86 0%~50% 43 Past due more than 181 days 750 100% 750 8,671 902

The movements of loss allowance were as follows:

	mont Septe	the nine hs ended mber 30, 2023	For the nine months ended September 30, 2022
Beginning balance	\$	985	805
Impairment losses recognized (gains on reversal of impairment)		(221)	704
Effect of changes in foreign exchange rates		1	92
Ending balance	\$	765	1,601

As of September 30, 2023, December 31 and September 30, 2022, the notes and accounts receivable were not discounted nor pledged.

(d) Other receivables (recognized as other current assets)

	September 30, December 31, 2023 2022		,	September 30, 2022
Other receivables	\$	20,194	56,976	45,839
Less: loss allowance		-		
	\$	20,194	56,976	45,839

As of September 30, 2023, December 31 and September 30, 2022, other receivables were not past due nor impaired.

The information on the Group's credit risk was disclosed in Note 6(aa).

(e) Inventories

	Sep	otember 30, 2023	December 31, 2022	September 30, 2022
Raw materials, supplies and spare parts	\$	3,780,381	4,377,047	4,327,762
Work in process		912,805	562,405	613,511
Finished goods		463,678	481,024	569,348
	\$	5,156,864	5,420,476	5,510,621

Except for cost of goods sold and inventories recognized as expenses, the remaining gains or losses which were recognized as operating cost or deduction of operating cost were as follows:

	m	or the three onths ended ptember 30, 2023		For the nine months ended September 30, 2023	For the nine months ended September 30, 2022
Losses on valuation of inventories and obsolescence	\$ _	2,050	13,127	12,449	204,888
Unallocated overheads	\$	16,667	75,625	53,717	163,830
Revenue from sale of scraps	\$	(9,683)	(12,526)	(26,775)	(42,020)
Losses (gains) on physical inventory count	\$	-	(459)	2,058	(5,706)

As of September 30, 2023, December 31 and September 30, 2022, the inventories were not pledged.

(f) Biological assets

(i) List of biological assets:

	September 30, 2023		December 31, 2022	September 30, 2022	
Consumable biological assets	\$	172,271	93,368	54,016	
Bearer biological assets	\$	235,860	273,554	318,468	

(ii) Movements in biological assets:

	mo	or the nine onths ended otember 30, 2023	For the nine months ended September 30, 2022
Beginning balance	\$	366,922	528,446
Increase due to purchase		4,652	26,089
Input costs		807,340	544,136
Depreciation expenses		(74,815)	(75,296)
Decrease due to sales and disposals		(692,781)	(668,956)
Changes in fair value less costs to sell due to price chang	es	(2,432)	4,244
Effect of changes in foreign exchange rates		(755)	13,821
Ending balance	\$	408,131	372,484
Current	\$	172,271	54,016
Non-current		235,860	318,468
	\$	408,131	372,484

For the three months and nine months ended September 30, 2023 and 2022, the gains and losses of \$23,381 thousand, \$(8,853) thousand, \$(2,432) thousand and \$4,244 thousand, respectively, were recognized as operating costs of the consolidated statement of comprehensive income as a result of the remeasurement of biological assets at the higher of its carrying amount or fair value less costs to sell.

(iii) The numbers of the Group's biological assets were as follows:

Unit: head

	September 30, 2023	December 31, 2022	September 30, 2022
Farrows, hogs and breeders	72,436	49,624	29,647

(iv) Fair value

There were no significant addition regarding the fair value of the Group's biological assets. For the related information, please refer to Note 6(f) of the consolidated financial statements for the year ended December 31, 2022.

(v) As of September 30, 2023, December 31 and September 30, 2022, the biological assets were not pledged.

(g) Investments accounted for using equity method

The components of investments accounted for using the equity method at the reporting date were as follows:

	September 30,	December 31,	September 30,
	2023	2022	2022
Associates	\$ 10,693,110	10,873,014	10,351,082

(i) Associates

Associates which are material to the Group consisted of the followings:

		Main Operating Location/ Registered	Proportion of Shareholding and Voting Rights				
Name of Associates	Main Businesses and Products	Country of the Company	September 30, 2023	December 31, 2022	September 30, 2022		
Jiangsu CM/Chainwin Agriculture Development Co., Ltd. (abbrev. Jiangsu CM/Chainwin)	e	China	49 %	49 %	49 %		
ITEQ Corporation (abbrev. ITEQ)	Manufactures and sells mass lamination boards, copper-clad laminates, prepreg, and electronic components	Taiwan	23.79 %	23.79 %	20.80 %		

The fair value of significant associate listed on the Taiwan Stock Exchange Corporation (TWSE) which is material to the Group is as follows:

		30, December 31,	_
	2023	2022	2022
ITEQ	\$ 7,874.	,320 6,268,373	4,659,070

The following consolidated financial information of significant associates has been adjusted according to individually prepared IFRS financial statements of these associates.

1) The consolidated financial information of Jiangsu CM/Chainwin:

	Sep	otember 30, 2023	December 31, 2022	September 30, 2022	
Current assets	\$	191,030	271,588	252,291	
Non-current assets		1,181,425	1,230,657	1,302,460	
Current liabilities		(111,723)	(72,676)	(148,152)	
Non-current liabilities		(28,081)	(30,026)	(31,953)	
Net assets	\$	1,232,651	1,399,543	1,374,646	

	For the three months ended September 30, 2023	For the three months ended September 30, 2022	For the nine months ended September 30, 2023	For the nine months ended September 30, 2022
Operating revenue	\$ 64,250	139,889	359,689	394,825
Profit (losses)	\$ (28,493)) 19,278	(169,288)	(43,109)
Other comprehensive income				
Total comprehensive income (loss)	\$(28,493)19,278	(169,288)	(43,109)
			For the nine months ended September 30, 2023	For the nine months ended September 30, 2022
Carrying amount of eattributable to the C			\$ 684,221	673,302
Losses attributable to	the Group		(82,951)	(21,123)
Exchange differences statements attributa		•	(30,144)	(69,354)
Shares of net assets of	f Jiangsu CM/Ch	ainwin at the end	571,126	582,825
Add: Effect of change	es in foreign exch	ange rates	31,239	89,144
Carrying amount of eattributable to the C		CM/Chainwin	\$ <u>602,365</u>	671,969

2) The consolidated financial information of ITEQ:

	September 30, 2023		December 31, 2022	September 30, 2022	
Current assets	\$	21,532,059	21,468,941	20,641,664	
Non-current assets		12,348,558	11,914,668	11,870,527	
Current liabilities		(10,741,357)	(10,883,035)	(10,324,043)	
Non-current liabilities	_	(3,384,651)	(2,389,588)	(2,190,616)	
Net assets	\$_	19,754,609	20,110,986	19,997,532	

	mo	r the three nths ended tember 30, 2023	For the three months ended September 30, 2022	n	For the nine nonths ended eptember 30, 2023	For the nine months ended September 30, 2022		
Operating revenue	\$	6,644,845	6,352,008	=	18,334,818	22,266,721		
Profit	\$	234,624	277,360		350,195	1,521,175		
Other comprehensive income		800,163	164,939	_	371,884	464,574		
Total comprehensive income	\$	1,034,787	442,299	_	722,079	1,985,749		
For the nine months ended more September 30,								
Carrying amount of e Group at the begin		of ITEQ attr	ributable to the	\$	10,143,903	9,678,934		
Profit attributable to	the G	roup			77,888	286,544		
Comprehensive incor	ne at	tributable to t	the Group		88,552	52,153		
Dividend received att	ribut	able to the G	roup		(259,024)	(398,211)		
Changes in retained e	arnir	gs of associa	ites		-	392		
Changes in capital surplus of associates				_	2,478	3,014		
Carrying amount of e Group at the end	quity	of ITEQ attr	ributable to the		10,053,797	9,622,826		
Less: Goodwill				_	(5,359,849)	(5,245,224)		
Shares of net assets o	f ITE	Q at the end		\$_	4,693,948	4,377,602		

Summary of financial information for the individually insignificant investments in associates accounted for using equity method were as follows. The aforementioned financial information was included in the consolidated financial statements of the Group:

	Sep	tember 30, 2023	December 31, 2022	September 30, 2022
Total equity of the individually insignificant investments in associates	\$	36,948	44,890	56,287

	moi	the three of the ended tember 30, 2023	For the three months ended September 30, 2022	For the nine months ended September 30, 2023	For the nine months ended September 30, 2022	
Attributable to the Group:						
Losses	\$	(13,818)	(56,733)	(10,150)	(6,166)	
Other comprehensive income						
Total comprehensive income (loss)	\$	(13,818)	(56,733)	(10,150)	(6,166)	

(ii) Pledge to secure

As of September 30, 2023, December 31 and September 30, 2022, the investments accounted for using equity method were not pledged.

(iii) Judgment of whether the Group has substantive control over its investee

The Group holds 49% of the outstanding voting shares of Rainbow Star Group Limited and is the single largest shareholder of the investee. The remaining 51% of Rainbow Star Group Limited's shares are concentrated within specific shareholders, and therefore the Group cannot obtain more than half of the total number of Rainbow Star Group Limited directors, and it also cannot obtain more than half of the voting rights at a shareholders' meeting. As a result, it is determined that the Group has significant influence but not control over Rainbow Star Group Limited.

The Group holds 23.79% of the outstanding voting shares of ITEQ Corporation (hereinafter referred to as "ITEQ") and is the single largest shareholder of the investee. Although the remaining 76.21% of ITEQ's shares are not concentrated within specific shareholders, the Group still cannot obtain more than half of the total number of ITEQ directors, and it also cannot obtain more than half of the voting rights at a shareholders' meeting. As a result, it is determined that the Group has significant influence but not control over ITEQ.

(h) Material non-controlling interests of subsidiaries

The material non-controlling interests of subsidiaries were as follows:

		Percentage of non-controlling interests						
		September 30,	December 31,	September 30,				
Subsidiaries	Registration	2023	2022	2022				
Chainwin Cayman	Cayman Islands	18.77 %	18.77 %	18.77 %				

The following information of the aforementioned subsidiaries have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers. Included in the information are the fair value adjustment made during the acquisition and relevant difference in accounting principles between the Group as at the acquisition date, intergroup transactions were not eliminated in this information:

			Sep	otember 30, 2023	December 31, 2022	September 30, 2022
Current assets			\$	3,348,713	3,110,612	3,570,090
Non-current assets				13,287,192	13,667,133	14,043,001
Current liabilities				(417,524)	(381,345)	(393,029)
Non-current liabilities				(8,746,759)	(7,273,176)	(7,544,451)
Net assets			\$	7,471,622	9,123,224	9,675,611
Non-controlling interests			\$	1,402,694	1,712,759	1,816,462
	mo	or the three onths ended otember 30, 2023	mo	or the three onths ended otember 30, 2022	For the nine months ended September 30, 2023	For the nine months ended September 30, 2022
Operating revenue	\$	176,978		92,075	440,885	288,648
Losses	\$	(567,806))	(514,173)	(1,832,007	(1,468,560)
Other comprehensive income		314,517		127,469	180,405	408,880
Total comprehensive income (loss)	\$	(253,289)) <u> </u>	(386,704)	(1,651,602	(1,059,680)
Losses attributable to non- controlling interests	\$	(106,598)) _	(96,529)	(343,934	(275,702)
Comprehensive income (loss), attributable to non-controlling interests	\$	(47,551)) _	(72,598)		
					For the nine months ended September 30, 2023	For the nine months ended September 30, 2022
Net cash flows used in operati	ng ac	etivities			\$ (874,304)	(972,494)
Net cash flows used in investig	ng ac	tivities			(258,997	(1,744,585)
Net cash flows from financing	activ	vities			757,922	658,110
Effect of changes in foreign ex	chan	ige rate			445,317	430,592
Increase (decrease) in cash and	d casl	h equivalents			\$ 69,938	(1,628,377)

(i) Property, plant and equipment

The movements in property, plant and equipment were as follows:

		Land	Buildings and structures	Machinery and equipment	Factory and equipment	Other equipment	Construction in progress and inspection- awaited devices	Total
Cost:								
Balance as of January 1, 2023	\$	2,546,534	9,478,472	17,648,311	6,689,192	668,701	9,406,592	46,437,802
Additions		1,214,619	295,606	256,877	466,025	31,589	543,330	2,808,046
Reclassification (Note 1)		-	1,688,559	2,181,502	1,701,540	25,797	(4,135,068)	1,462,330
Disposals		-	(19,429)	(2,162,190)	(717,602)	(150,659)	-	(3,049,880)
Effect of changes in foreign exchange rate	s _	-	20,735	(769)	9,653	254	(9,084)	20,789
Balance as of September 30, 2023	\$_	3,761,153	11,463,943	17,923,731	8,148,808	575,682	5,805,770	47,679,087
Balance as of January 1, 2022	\$	2,546,534	5,409,451	20,272,516	6,406,045	565,461	9,402,246	44,602,253
Additions		-	335	510,587	211,996	106,868	3,675,955	4,505,741
Reclassification (Note 2)		-	(32,022)	1,573,227	18,162	45,172	480,648	2,085,187
Disposals		-	(108,968)	(3,458,899)	(597,241)	(38,336)	-	(4,203,444)
Effect of changes in foreign exchange rate	s _	-	78,682	300	1,560	2,362	252,834	335,738
Balance as of September 30, 2022	\$_	2,546,534	5,347,478	18,897,731	6,040,522	681,527	13,811,683	47,325,475
Accumulated depreciation:	_							
Balance as of January 1, 2023	\$	-	1,193,693	10,327,673	3,073,301	297,129	-	14,891,796
Depreciation		-	390,064	2,250,879	518,646	113,998	-	3,273,587
Disposals		-	(19,429)	(2,161,387)	(716,223)	(128,365)	-	(3,025,404)
Effect of changes in foreign exchange rate	s _	-	1,778	238	575	156		2,747
Balance as of September 30, 2023	\$_		1,566,106	10,417,403	2,876,299	282,918		15,142,726
Balance as of January 1, 2022	\$	-	1,045,218	12,327,474	3,213,613	231,951	-	16,818,256
Depreciation		-	194,879	2,235,026	424,708	124,072	-	2,978,685
Disposals		-	(108,941)	(3,415,461)	(595,964)	(38,336)	-	(4,158,702)
Effect of changes in foreign exchange rate	s _	-	1,708	159	735	998		3,600
Balance as of September 30, 2022	\$_		1,132,864	11,147,198	3,043,092	318,685		15,641,839
Carrying amount:	_							
Balance as of January 1, 2023	\$_	2,546,534	8,284,779	7,320,638	3,615,891	371,572	9,406,592	31,546,006
Balance as of September 30, 2023	\$	3,761,153	9,897,837	7,506,328	5,272,509	292,764	5,805,770	32,536,361
Balance as of January 1, 2022	\$	2,546,534	4,364,233	7,945,042	3,192,432	333,510	9,402,246	27,783,997
Balance as of September 30, 2022	\$	2,546,534	4,214,614	7,750,533	2,997,430	362,842	13,811,683	31,683,636

Note 1: Inventories and prepayments for business facilities were reclassified as property, plant and equipment. Beside, property, plant and equipment were transferred to other expenses and adjusted by using the construction refund.

(i) Pledge to secure

As of September 30, 2023, December 31 and September 30, 2022, the property, plant and equipment was subject to a registered debenture to secured bank loans and line of credit, the collateral for these long-term borrowings was disclosed in Note 8.

Note 2: Inventories, prepayments for business facilities, capitalized right-of-use depreciation expenses and other current assets were reclassified as property, plant and equipment. Beside, property, plant and equipment were adjusted by using the construction refund.

(ii) Property, plant and equipment under construction

The Group rented some pieces of land and entered into different agreements for the construction of its new factories on the said lands. For the nine months ended September 30, 2023, the Group has constructed factories amounting to \$564,055 thousand, and has recognized as construction in progress. As of September 30, 2023, the total amount of the construction was \$5,083,705 thousand, and was recognized as construction in progress.

(iii) For the three months and nine months ended September 30, 2023 and 2022, capitalized interest expenses amounted to \$41,577 thousand, \$53,257 thousand, \$136,468 thousand and \$96,104 thousand, respectively. The annual interest rates at which these interest expenses were capitalized ranged from 1.41%~6.24%, 0.90%~3.12%, 1.14%~6.24% and 0.57%~3.12%, respectively.

(j) Right-of-use assets

The movements in right-of-use assets were as follows:

		Buildings		
		and	Other	
_	Land	structures	<u>equipment</u>	Total
Cost:				
Balance as of January 1, 2023 \$	881,493	474,148	21,021	1,376,662
Additions	96	5,183	6,778	12,057
Disposals	(13,540)	(20,286)	(5,856)	(39,682)
Effect of change in foreign exchange rates	676	75	2	753
Balance as of September 30, 2023 \$_	868,725	459,120	21,945	1,349,790
Balance as of January 1, 2022	986,869	482,647	20,853	1,490,369
Additions	67,209	83,812	638	151,659
Disposals	(137,947)	(94,419)	(964)	(233,330)
Effect of change in foreign exchange rates	13,317	1,804	104	15,225
Balance as of September 30, 2022 \$_	929,448	473,844	20,631	1,423,923
Accumulated depreciation:				
Balance as of January 1, 2023 \$	133,545	132,395	10,993	276,933
Depreciation	41,146	32,931	4,364	78,441
Disposals	(8,650)	(20,286)	(5,618)	(34,554)
Effect of change in foreign exchange rates	203	27	3	233
Balance as of September 30, 2023 \$_	166,244	145,067	9,742	321,053
Balance as of January 1, 2022 \$	108,020	120,945	5,788	234,753
Depreciation (Note)	42,265	41,927	4,627	88,819
Disposals	(29,377)	(42,375)	(964)	(72,716)
Effect of change in foreign exchange rates	1,755	205	11	1,971
Balance as of September 30, 2022 \$_	122,663	120,702	9,462	252,827

Carrying amount:	Land	Buildings and structures	Other equipment	Total
Balance as of January 1, 2023	747,948	341,753	10,028	1,099,729
Balance as of September 30, 2023 \$	702,481	314,053	12,203	1,028,737
Balance as of January 1, 2022	878,849	361,702	15,065	1,255,616
Balance as of September 30, 2022	806,785	353,142	11,169	1,171,096

Note: Including capitalized depreciation expenses transferred to construction in progress, which amounted to \$46 thousand.

(k) Investment property

		Land	Buildings and structures	Total
Carrying amount:	'			
Balance as of January 1, 2023	\$	963,127	<u>85,505</u>	1,048,632
Balance as of September 30, 2023	\$	963,127	81,517	1,044,644
Balance as of January 1, 2022	\$	963,127	90,821	1,053,948
Balance as of September 30, 2022	\$	963,127	86,834	1,049,961
Fair value:				
Balance as of January 1, 2023			9	1,166,818
Balance as of September 30, 2023			9	1,155,172
Balance as of September 30, 2022			9	1,166,666

There was no significant additions, disposals, or recognition and reversal of impairment losses of investment property for the nine months ended September 30, 2023 and 2022. As of September 30, 2023, amortization of investment property was disclosed in Note 12(a). Other information was disclosed in Note 6(m) of the consolidated financial statements for the year ended December 31, 2022.

When measuring the fair value of its investment property, the Group considered the present value of net cash flows to be generated from leasing the property. The expected net cash flows were discounted using the yield to reflect its specified inherit risk on the net cash flows. The inputs to the valuation technique used for measuring fair value were categorized as a Level 2 fair value. As of September 30, 2023, December 31 and September 30, 2022, the yield applied to the net annual rentals to determine fair value of property for which current prices in an active market were unavailable, was as follows:

	September 30,	December 31,	September 30,
Location	2023	2022	2022
Hsinchu	0.30%	0.44%	0.44%

As of September 30, 2023, December 31 and September 30, 2022, the investment properties were not pledged.

(l) Intangible assets

	chnical ow-how	Computer software and information systems	Goodwill	Others	Total
Carrying amount:					
Balance as of January 1, 2023	\$ 35,792	201,522	324,962	29	562,305
Balance as of September 30, 2023	\$ 31,403	169,582	331,426	17,912	550,323
Balance as of January 1, 2022	\$ 44,318	284,449	312,405	713	641,885
Balance as of September 30, 2022	\$ 37,522	218,852	329,272	55	585,701

There was no significant additions, disposals, or recognition and reversal of impairment losses of intangible assets for the nine months ended September 30, 2023 and 2022. As of September 30, 2023, amortization of intangible assets was disclosed in Note 12(a). Other information was disclosed in Note 6(n) of the consolidated financial statements for the year ended December 31, 2022.

As of September 30, 2023, December 31 and September 30, 2022, the intangible assets were not pledged.

(m) Other current assets and other non-current assets

	Sep	tember 30, 2023	December 31, 2022	September 30, 2022
Tax refund receivables	\$	77,260	41,268	123,892
Other receivables		20,194	56,976	45,839
Prepayments to suppliers		1,701	142	-
Prepaid expenses		82,062	128,128	69,637
Offset against business tax payable		43,431	43,857	41,615
Restricted assets		290,588	269,261	356,564
Refundable deposits		98,533	148,689	149,717
Long-term prepayments to suppliers		75,239	55,424	36,074
Others		21,095	24,830	28,554
	\$	710,103	768,575	<u>851,892</u>

(n) Short-term borrowings

		otember 30, 2023	December 31, 2022	September 30, 2022	
Secured short-term borrowings (in RMB)	\$	21,556		18,805	
Unsecured short-term borrowings	\$				
Unused bank credit lines for short-term borrowings	\$	1,672,493	1,205,517	1,621,912	
Unused bank credit lines for short-term and long-term borrowings	\$	3,905,000	3,308,682	3,408,698	
Annual interest rate	_	3.7%	<u>-</u>	3.75%	

The collateral for these short-term borrowings were disclosed in Note 8.

(o) Long-term borrowings

	S	eptember 30, 2023	December 31, 2022	September 30, 2022
Secured long-term borrowings (in TWD)	\$	1,200,000	-	-
Secured long-term syndicated borrowings (in USD)		8,482,766	6,984,198	7,211,956
Unsecured long-term borrowings (in TWD)		10,233,020	10,617,247	10,190,747
Less: Current portion	_	(3,517,680)	(1,731,147)	(989,227)
Total	\$_	16,398,106	15,870,298	16,413,476
Unused bank credit lines for long-term borrowings	\$_	14,591,950	13,358,568	13,757,868
Annual interest rate	_	1%~5.83%	0.75%~4.62%	0.75%~3.06%
Expiry date	202	4/05/17~2038/08/14	2024/05/17~2029/01/20	2024/05/17~2029/01/20

As of September 30, 2023, the remaining balances of the borrowing due were as follows:

Redemption period	Amount
October 1, 2023~September 30, 2024	\$ 3,517,680
October 1, 2024~September 30, 2025	14,117,048
October 1, 2025~September 30, 2026	474,808
October 1, 2026~September 30, 2027	374,808
October 1, 2027 and after	1,431,442
	\$ <u>19,915,786</u>

- (i) The unused bank credit lines for short-term and long-term borrowings at the reporting date were disclosed in Note 6(n).
- (ii) The collateral for these long-term borrowings were disclosed in Note 8.
- (iii) In December 2021, the Group entered into a three-year syndicated loan agreement with Far Eastern International Bank and other ten banks. The total credit facility under this loan agreement is US\$300,000 thousand.

The related financial covenants and restrictions for the syndicated loans mentioned above were as follows:

- 1) At the end of reporting period, current ratio (current assets / current liabilities): shall not lower than 100%;
- 2) Interest coverage ratio [(profit before tax + depreciation + amortization + interest expense) / interest expense)]: shall not be lower than 100%; and
- 3) Tangible net assets value (equity intangible assets): shall not be lower than NT\$20,000,000 thousand.

After the guarantor signs the loan agreement, the aforementioned financial ratio and criteria will be reviewed semi-annually, which are based on the year-end consolidated financial statements audited by the Certified Public Accountants (CPAs) that are approved by the leading bank, as well as the semi-annual consolidated financial statements reviewed by the CPAs.

Although the Group breached the above restriction of the current ratio in the second quarter of 2023, the Group was able to obtain a waiver letter in June 2023 after negotiating with the banks. Hence, the Group need not have to repay the loans immediately.

For the year ended December 31, 2022 and for the six months ended June 30, 2022, the Group were in compliance with the above financial covenants and restrictions.

(p) Bonds payable

The details of bonds payable were as follows:

	Sep	otember 30, 2023	December 31, 2022	September 30, 2022
Overseas convertible bonds issuance balance	\$	5,428,896	11,092,858	12,284,976
Less: Unamortized discounted bonds payable		(156,718)	(423,303)	(506,603)
Current portion		(5,272,178)		
Total	\$ <u></u>	-	10,669,555	11,778,373

Proceeds from issuance (less transaction cost amounted to \$89,226 thousand)	\$	13,902,774
Equity components (less transaction cost amortized to equity component of \$4,147	,	(639,583)
thousand)		
Embedded derivatives instruments—put/ call options	_	(139,920)
Liability components at the issuance date (less transaction cost allocated to liability	y	13,123,271
component of \$85,079 thousand)		
Interest expense at an effective interest rate of 1.28%		400,774
Repurchases of bonds payable	_	(8,251,867)
Liability components at September 30, 2023	\$	5,272,178

The Company resolved to issue the first unsecured overseas convertible bonds, as proposed in the Board of Directors meeting held on November 27, 2020, which had been approved by the Financial Supervisory Commission with approval No.1090377907 on December 25, 2020 and been issued on the Singapore Exchange Securities Trading Limited on January 14, 2021. The Company issued the 5 years unsecured convertible bond, amounting to US\$500,000 thousand without coupon rate, with the maturity dates on January 14, 2026.

Unless previously redeemed, repurchased, and cancelled or converted, regulations and except during the closed period, the bonds may be converted into the Company's common shares pursuant to the applicable laws and regulations and the indenture at any time starting from the next day immediately after three months from the issue date to (1) the 10 day prior to the maturity date or (2) the 5 business day prior to the applicable redemption date on which a bondholder exercises its put right or the applicable date (other than the maturity date) on which the Company exercises its redemption right.

The conversion price was 140% of the closing price of the Company's common shares on the Taipei Exchange on the pricing date, which was NT\$497. The number of common shares to be delivered upon conversion of any bond will be determined with the principal amount of the bonds multiplied by the fixed exchange rate, which is NT\$27.984 to US\$1, which as determined on the pricing date and divided by the conversion price in effect on the date of conversion. After the issuance of the bonds, the conversion price shall be adjusted in accordance with the relevant anti-dilution provisions of the indenture. As of September 30, 2023, the conversion price was adjusted to NT\$457.13 per share.

The above-mentioned convertible bonds included liabilities and equity components. The equity component was accounted under the capital surplus-stock option. The effective interest rate originally recognized for the liability component was 1.28%.

For the nine months ended September 30, 2023 and 2022, the Company has repurchased the first issued unsecured overseas convertible bonds in 2020 at the principle amount of US\$202,400 thousand and US\$61,000 thousand, respectively, and consequently, derecognized the related derivative financial liabilities. The difference between the repurchased amount and the carrying amount was recognized under other gains and losses. Plese refer to Note 6 (z).

(q) Lease liabilities

The carrying amounts of lease liabilities were as follow:

	September 30, 2023	December 31, 2022	September 30, 2022	
Current	\$	103,570	113,276	
Non-current	\$ 865,224	924,832	976,907	

For the maturity analysis, please refer to Note 6(aa).

The amounts recognized in profit or loss were as follows:

	For the three months ended September 30, 2023		For the three months ended September 30, 2022	For the nine months ended September 30, 2023	For the nine months ended September 30, 2022	
Interest expenses on lease liabilities Expenses relating to	\$	5,639	6,526	17,370	20,191	
short-term leases Expenses relating to leases of low-value assets, excluding	\$	755	1,147	2,986	4,711	
short-term leases of low-value assets	\$	370	407	1,164	1,169	

The amounts recognized in the statement of cash flows for the Group was as follows:

	For the nine	For the nine
	months ended	months ended
	September 30	September 30,
	2023	2022
Total cash outflow for leases	\$ 84,5	04 112,471

(i) Land, buildings and structures leases

The Group leases land, buildings and structures for its plants, parking lots and staff dormitories. The leases of them typically run for a period of 2 to 50 years.

(ii) Other leases

The Group leases printer and transportation equipment, with lease terms of 2 to 10 years.

(iii) Others

Parts of the leases of transportation equipment, machinery and equipment, office and staff dormitories are with contract terms of less than one year. These leases are short-term. The Group has elected not to recognize right-of-use assets and lease liabilities for these leases. Also, some leases contain cancellation options exercisable by the Group. In which lease is not reasonably certain to use an optional extended lease term, payments associated with the optional period are not included within lease liabilities.

(r) Operating lease

There were no significant changes in operating lease for the nine months ended September 30, 2023 and 2022. Please refer to Note 6(t) of the consolidated financial statements for the year ended December 31, 2022 for other related information.

(s) Employee benefits

(i) Defined benefit plans

At the end of the prior fiscal year, there was no material volatility of the market, no material reimbursement and settlement or other material one-time events. As a result, pension cost in the consolidated interim financial statements was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate as of December 31, 2022 and 2021.

The Group's expenses recognized in profit or loss were as follows:

	For the three months ended September 30, 2023		For the three months ended September 30, 2022	For the nine months ended September 30, 2023	For the nine months ended September 30, 2022
Operating costs	\$	-	-	-	-
Operating expenses		591	450	1,773	1,350
	\$	591	450	1,773	1,350

(ii) Defined contribution plans

The Group's expenses under the pension plan cost to the Bureau of Labor Insurance were as follows:

	For the three months ended September 30, 2023		For the three months ended September 30, 2022	For the nine months ended September 30, 2023	For the nine months ended September 30, 2022	
Operating costs	\$	23,305	24,039	70,778	76,712	
Operating expenses		7,925	7,182	23,502	21,577	
	\$	31,230	31,221	94,280	98,289	

(iii) The Group's mainland China subsidiaries have a defined contribution plan. Monthly contributions to an independent fund administered by the government in accordance with the pension regulations in the People's Republic of China (PRC) are based on certain percentage of employees' monthly salaries and wages. Other than the monthly contributions, the Group has no further obligations. For the three months and nine months ended September 30, 2023 and 2022, the Group recognized the pension costs in accordance with the pension regulations and amounted to \$4,048 thousand, \$4,542 thousand, \$13,174 thousand and \$13,929 thousand, respectively.

(t) Income tax

(i) The amount of income tax expense (benifit) was as follows:

	For the three	For the three	For the nine	For the nine
	months ended	months ended	months ended	months ended
	September 30, 2023	September 30, 2022	September 30, 2023	September 30, 2022
Income tax expense				
(benifit)	\$36,862	54,594	(125,670)	383,803

(ii) There was no income tax expense recognized in other comprehensive income for the nine months ended September 30, 2023 and 2022.

(iii) Assessment

The Company's corporate income tax returns for all the years through 2020 were assessed by the tax authorities.

(u) Capital and other equity

Except for the following disclosure, there was no significant change for capital and other equity for the nine months ended September 30, 2023 and 2022. For the related information, please refer to Note 6(w) of the consolidated financial statements for the year ended December 31, 2022.

(i) On August 12, 2022, the Company's Board of Directors approved a resolution to redeem the unvested restricted employee share of stock amounting to 36 thousand shares, at \$10 dollars par value per share, amounting to \$360 thousand. The recognition date for capital reduction was August 31, 2022. All related registration had been completed. There was no such transaction for the nine months ended September 30, 2023.

(ii) Capital surplus

Balance of capital surplus at the reporting date were as follows:

	Se	ptember 30, 2023	December 31, 2022	September 30, 2022
Additional paid-in capital	\$	9,234,813	9,234,813	9,234,813
Equity component of convertible bonds		639,583	639,583	639,583
Changes in ownership interests in subsidiaries		85,565	85,565	85,565
Changes in equity of associates accounted for using equity method		3,360	882	3,524
Employee stock options		3,245	3,245	3,245
	\$ <u></u>	9,966,566	9,964,088	9,966,730

(iii) Retained earnings

The Company's Articles of Incorporation stipulate that 10% of the balance of annual income or earnings after deducting accumulated deficit, if any, must be set aside as a legal reserve and a special capital reserve is likewise appropriated or the annual income or earnings are retained in accordance with the relevant laws or regulations or as requested by the authorities, but the balance of such legal reserve reaches an amount equal to the paid-in capital, the appropriation to legal reserves is discontinued. Otherwise, the Company shall set aside at least 50% for shareholder, the distribution of remaining balance of the earnings should be further proposed by the Board of Directors and resolved by the shareholders' meeting. And the cash dividends should not lower than 10% of the total stockholders' dividends.

It is authorized the distributable dividends and bonuses or legal capital reserve and capital reserve in whole or in part may be paid in cash after a resolution has been adopted by a majority vote at a meeting of the Board of Directors attended by two-thirds of the total number of directors; and in addition thereto a report of such distribution shall be submitted to the shareholders' meeting.

As the Company is a technology and capital-intensive enterprise and is in its growth phase, it has adopted a more prudent approach in appropriating its remaining earnings as its dividend policy in order to sustain its long-term capital needs and thereby maintain continuous development and steady growth.

The appropriations of earning for 2022 and 2021 had been approved in the meeting of Board of Directors held on March 9, 2023 and March 18, 2022, respectively. The appropriations and dividends were as follows:

	 2022	2021
Cash dividends	\$ 1,059,851	3,391,811

The related information mentioned above can be found on websites such as the Market Observation Post System.

(iv) Other equity interests, net of tax

	diff trai forei	xchange erences on nslation of gn financial atements	Unrealized gains (losses) on financial assets at fair value through other comprehensive income	
Balance as of January 1, 2023	\$	61,004	712,629	
Foreign currency differences (net of tax):				
The Group		212,418	-	
Associates		59,493	-	
Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax):				
The Group		-	1,240,563	
Associates		-	4,389	
Balance as of September 30, 2023	\$	332,915	1,957,581	
	diffe trai foreiş	schange erences on uslation of gn financial atements	Unrealized gains (losses) on financial assets at fair value through other comprehensive income	Other unearned compensation for restricted shares of employees
Balance as of January 1, 2022	\$	(269,409)	1,044,071	(6,597)
Foreign currency differences (net of tax):				
The Group		479,177	-	-
Associates		(6,064)	-	-
Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax):				
The Group		-	(494,755)	-
Associates		-	1,399	-
Cumulative gains (losses) reclassified to retained earnings on disposal of investments in equity instruments at fair value through other comprehensive income (net of tax)		_	(18,830)	-
Forfeiture of unvested restricted shares of employee		-	_	6,558
Compensation cost arising from restricted shares of				
employees	_			39

(v) Share-based payment

Except for the following disclosure, there were no significant changes for share-based payment for the nine months ended September 30, 2023 and 2022. For the related information, please refer to Note 6(x) of the consolidated financial statements for the year ended December 31, 2022.

(i) The Company issued restricted shares of stock (RSA) for employees

On May 13, 2022, the Company took back unvested restricted employee share of stock amounting to 36 thousand shares. For the nine months ended September 30, 2022, there were 226 thousand vested shares. As of September 30, 2022, there were 0 thousand shares outstanding.

For the three months and nine months ended September 30, 2022, the Company recognized the compensation cost of \$0 thousand and \$39 thousand for the aforementioned RSA, respectively. For the nine months ended September 30, 2023, there was no compensation cost arising from share-based payment.

(ii) The employee stock option (ESOPs) of subsidiary (PBL)

For the three months and the nine months ended September 30, 2023 and 2022, PBL recognized the compensation cost of \$2,196 thousand, \$5,638 thousand, \$9,882 thousand and \$11,212 thousand for the aforementioned ESOPs, respectively.

(w) Earnings per share ("EPS")

	For the three months ended September 30, 2023		For the three months ended September 30, 2022	For the nine months ended September 30, 2023	For the nine months ended September 30, 2022
Basic earnings per share:					
Profit (loss) belonging to common shareholders	\$ <u></u>	34,033	351,809	(464,701)	1,878,060
Weighted-average number of outstanding shares of common stock (in thousands shares)		423,940	423,940	423,940	423,830
Basic earnings per share (in dollars)	\$	0.08	0.83	(1.10)	

	For the three months ended September 30, 2023	For the three months ended September 30, 2022	For the nine months ended September 30, 2023	For the nine months ended September 30, 2022
Diluted earnings per share:				
Profit (loss) belonging to common shareholders	\$ 34,033	3 351,809	(464,701)	1,878,060
Interest expense and other gains and losses on convertible bonds, net of tax	-	(237,034)	(55,815)	-
Profit (loss) belonging to common shareholders (diluted)	\$34,033	3 114,775	(520,516)	1,878,060
Weighted-average number of outstanding shares of common stock (in thousands shares)	423,940	0 423,940	423,940	423,830
Effect of potentially dilutive common stock				
Employee remuneration (in thousands shares)	-	1,090	-	1,510
Restricted employee shares (in thousands shares)	-	-	-	110
Effect of conversion of convertible bonds (in thousands shares)		29,630	18,374	
Weighted-average number of common stock (diluted) (in thousands shares)	423,94	0 454,660	442,314	425,450
Diluted earnings per share (in dollars)	\$ 0.03	0.25	(1.18)	4.41

For the three months and nine months ended September 30, 2023, the employee compensation had anti-diluted effects and hence the employee compensation was not included in the calculation of effect on potentially diluted common stock. Furthermore, for the three months ended September 30, 2023 and nine months ended September 30, 2022, the convertible bonds had anti-diluted effects if the bonds were converted, and hence the convertible bonds were not included in the calculation of effect on potentially diluted common stock.

(x) Revenue from contracts with customers

(i) Disaggregation of revenue

	For the three months ended September 30, 2023									
		Segment- Foundry	Segment- Agriculture technology	Segment- Others (Note)	Total					
Primary geographical markets:										
Asia	\$	2,998,583	176,923	(127,940)	3,047,566					
Americas		702,814	-	11,051	713,865					
Taiwan		131,511	55	23,922	155,488					
Europe	_	251,759		(3,668)	248,091					
	\$	4,084,667	176,978	(96,635)	4,165,010					
Main product/ services lines:	-									
Foundry	\$	4,084,667	-	-	4,084,667					
Others	_	-	176,978	(96,635)	80,343					
	\$	4,084,667	176,978	(96,635)	4,165,010					
				ed September 30	0, 2022					
	_		ree months end Segment- Agriculture	ed September 30 Segment- Others (Note)), 2022 Total					
Primary geographical markets:	_	For the th	ree months end Segment-	Segment- Others						
Primary geographical markets:	_	For the th	ree months end Segment- Agriculture	Segment- Others						
	_	For the th Segment- Foundry	ree months end Segment- Agriculture technology	Segment- Others (Note)	Total					
Asia	_	For the the Segment-Foundry 2,090,485	ree months end Segment- Agriculture technology	Segment- Others (Note)	Total 2,183,397					
Asia Americas	_	For the th Segment- Foundry 2,090,485 1,290,736	ree months end Segment- Agriculture technology 92,072	Segment- Others (Note) 840 9,609	Total 2,183,397 1,300,345					
Asia Americas Taiwan	_	For the th Segment- Foundry 2,090,485 1,290,736 205,401	ree months end Segment- Agriculture technology 92,072	Segment- Others (Note) 840 9,609 28,596	Total 2,183,397 1,300,345 234,000					
Asia Americas Taiwan	\$	For the th Segment- Foundry 2,090,485 1,290,736 205,401 247,733	ree months end Segment- Agriculture technology 92,072 - 3	Segment- Others (Note) 840 9,609 28,596 (56,733)	Total 2,183,397 1,300,345 234,000 191,000					
Asia Americas Taiwan Europe	\$	For the th Segment- Foundry 2,090,485 1,290,736 205,401 247,733	ree months end Segment- Agriculture technology 92,072 - 3	Segment- Others (Note) 840 9,609 28,596 (56,733)	Total 2,183,397 1,300,345 234,000 191,000					
Asia Americas Taiwan Europe Main product/ services lines:	\$ \$	For the th Segment- Foundry 2,090,485 1,290,736 205,401 247,733 3,834,355	ree months end Segment- Agriculture technology 92,072 - 3	Segment- Others (Note) 840 9,609 28,596 (56,733)	Total 2,183,397 1,300,345 234,000 191,000 3,908,742					

		For the nine months ended September 30, 2023						
		Segment- Foundry	Segment- Agriculture technology	Segment- Others (Note)	Total			
Primary geographical markets:								
Asia	\$	7,361,935	438,675	136,770	7,937,380			
Americas		1,936,074	-	32,227	1,968,301			
Taiwan		403,266	2,210	62,462	467,938			
Europe	_	594,843			594,843			
	\$_	10,296,118	440,885	231,459	10,968,462			
Main product/ services lines:								
Foundry	\$	10,290,606	-	-	10,290,606			
Others	_	5,512	440,885	231,459	677,856			
	\$_	10,296,118	440,885	231,459	10,968,462			

For the nine months ended September 30, 2022 Segment-Segment-Segment-Agriculture **Others Foundry** technology (Note) **Total** Primary geographical markets: Asia \$ 8,076,767 288,624 7,220 8,372,611 Americas 4,988,961 27,466 5,016,427 Taiwan 719,072 24 106,088 825,184 595,004 (6,166)588,838 Europe 288,648 134,608 14,379,804 14,803,060 Main product/ services lines: Foundry 14,379,804 14,379,804 Others 288,648 134,608 423,256 14,379,804 288,648 134,608 14,803,060

Note: Segment-others were mainly general investment businesses, and their net investment profits and losses were recognized as operating revenue.

(ii) Balance of contracts

	Sep	tember 30, 2023	December 31, 2022	September 30, 2022	
Notes receivable	\$	1,071	1,310	830	
Accounts receivable		1,206,174	916,315	1,312,997	
Less: loss allowance		(765)	(985)	(1,601)	
	\$	1,206,480	916,640	1,312,226	
Contract liabilities	\$	442,779	235,309	214,889	

For details of notes and accounts receivable and allowance for impairment, please refer to Note 6(c).

The major change in the balance of contract liabilities is the difference between the time frame in the performance obligation to be satisfied and the payment to be received. The amount of revenue recognized for the nine months ended September 30, 2023 and 2022 that was included in the contract liabilities balance at the beginning of the period was \$182,279 thousand and \$298,485 thousand, respectively.

(y) Employees' and directors' remuneration

According to the Company's Article of Incorporation, if there is any net profit after closing of a fiscal year, it shall be allocated according to the following principles:

- (i) Employees' remuneration: not less than 5% but no more than 10% shall be distributed in the form of shares or cash. Stock-type employee remuneration may be distributed to qualified employees of affiliates of the Company.
- (ii) Directors's remuneration: no more than 3%.

However, if there are any accumulated losses of the Company, the Company shall pre-reserve the amount to offset the loss. The distribution of employees' remuneration and directors's remuneration shall follow the special resolution by Board of Directors, and report it to the shareholders' meeting.

The Company estimated its employees' and directors' remuneration as follows:

	mo	For the three months ended September 30, 2023 For the three months ende September 30 2022		months ended	For the nine months ended September 30, 2022
Employees' remuneration	\$	-	8,624	-	134,624
Directors' remuneration		-	7,000		43,000
	\$	-	15,624		177,624

The amount of employees' remuneration, and directors' remuneration were estimated based on profit before tax, net of the amount of the remuneration and accumulated losses, and then multiplied by the rule of Company's Article of Incorporation. The above remuneration was included in the operating costs and operating expenses of for the three months and nine months ended September 30, 2023 and 2022. The differences between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statements, if any, shall be accounted for as changes in accounting estimates and recognized in profit or loss in the following year.

For the years ended December 31, 2022 and 2021, the Company accrued and recognized its employees' remuneration amounting to \$149,000 thousand and \$447,000 thousand, and directors' remuneration amounting to \$38,000 thousand and \$129,000 thousand, respectively. There were no difference between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statements. The related information mentioned above can be found on websites such as the Market Observation Post System.

(z) Non-operating income and expenses

(i) Interest income

	mo	r the three nths ended tember 30, 2023	For the three months ended September 30, 2022	For the nine months ended September 30, 2023	For the nine months ended September 30, 2022	
Interest income from bank deposits	\$	29,378	21,532	156,654	42,873	
Other interest income		16	9	66	32	
Interest income	\$	29,394	21,541	156,720	42,905	

(ii) Other income

	moi	the three of the ended tember 30, 2023		For the nine months ended September 30, 2023	For the nine months ended September 30, 2022	
Dividend income	\$	16,887	25,651	33,053	178,267	
Rent income		9,514	10,297	30,518	28,832	
Other income	\$	26,401	35,948	63,571	207,099	

For the nine

months ended

WIN Semiconductors Corp. and Subsidiaries Notes to the Consolidated Financial Statements

For the three

For the nine

months ended months ended

For the three

months ended

(iii) Other gains and losses

		Sep	tember 30, 2023	September 30, 2022	September 30, 2023	September 30, 2022
	Gains (losses) on disposals of property, plant and equipment	\$	4,132	28,940	(18,694)	36,001
	Foreign exchange gains (losses)		(121,435)	70,568	(777,462)	509,519
	Gains (losses) on financial assets or liabilities at fair value through profit or loss		(121,627)	18,642	26,273	(560,799)
	Gains on repurchases of bonds payable		157,344	360,101	712,679	360,101
	Gains (losses) on lease modification		(18)	(2,432)	24	(26,426)
	Government grants		46,693	-	48,693	-
	Others		10,074	(2,190)	10,381	(40,294)
	Other gains and losses	\$	(24,837)	473,629	1,894	278,102
(iv)	Finance costs					
		mo	r the three nths ended tember 30, 2023	For the three months ended September 30, 2022	For the nine months ended September 30, 2023	For the nine months ended September 30, 2022
	Interest expenses					
	Bank borrowings	\$	191,689	89,867	526,069	195,345
	Bonds payable		17,797	41,536	76,219	126,975
	Lease liabilities		5,639	6,526	17,370	20,237
	Less: capitalized interest		(41,577)	(53,257)	(136,468)	(96,104)
	Subtotal of interest expenses		173,548	84,672	483,190	246,453
	Other finance costs		162	36	485	108
	Finance costs	\$	173,710	84,708	483,675	246,561

(aa) Financial instruments

Except for the contention mentioned below, there was no significant change in the fair value of the Group's financial instruments and degree of exposure to credit risk, liquidity risk and market risk arising from financial instruments. For the related information, please refer to Note 6(ac) of the consolidated financial statements for the year ended December 31, 2022.

(i) Credit risk

1) Receivables and debt securities

For information on credit risk regarding notes and accounts receivable, please refer to Note 6(c).

Other financial assets measured at amortized cost include other receivables. For related information of investment and impairment, please refer to Note 6(d).

All of these financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited 12 months expected losses.

(ii) Liquidity risk

The following were the contractual maturities of financial liabilities:

	Carrying amount	Contractual cash flows	Within 1 year	1-2 years	2-5 years	Over 5 years
As of September 30, 2023						•
Non-derivative financial liabilities						
Secured bank loans	\$ 9,704,322	10,895,380	544,840	9,001,953	341,268	1,007,319
Unsecured bank loans	10,233,020	10,439,168	3,635,791	5,684,600	976,920	141,857
Bonds payable	5,272,178	5,268,051	5,268,051	-	-	-
Notes and accounts payable	1,590,315	1,590,315	1,590,315	-	-	-
Other payables	2,220,754	2,220,754	2,220,754	-	-	-
Guarantee deposits received	120,170	120,170	1,584	8,586	-	110,000
Lease liabilities	972,585	1,160,724	118,348	105,823	256,141	680,412
	\$ 30,113,344	31,694,562	13,379,683	14,800,962	1,574,329	1,939,588
As of December 31, 2022						
Non-derivative financial liabilities						
Secured bank loans	\$ 6,984,198	8,183,035	326,332	326,331	7,530,372	-
Unsecured bank loans	10,617,247	10,874,528	1,855,307	3,705,258	5,030,702	283,261
Bonds payable	10,669,555	10,764,204	-	10,764,204	-	-
Notes and accounts payable	1,016,716	1,016,716	1,016,716	-	-	-
Other payables	2,362,432	2,362,432	2,362,432	-	-	-
Guarantee deposits received	119,299	119,299	610	8,689	-	110,000
Lease liabilities	1,028,402	1,233,131	114,743	107,306	284,170	726,912
	\$ <u>32,797,849</u>	34,553,345	5,676,140	14,911,788	12,845,244	1,120,173

	Carrying amount	Contractual cash flows	Within 1 year	1-2 years	2-5 years	Over 5 years
As of September 30, 2022						
Non-derivative financial liabilities						
Secured bank loans	\$ 7,230,761	8,089,214	242,718	223,749	7,622,747	-
Unsecured bank loans	10,190,747	10,420,340	1,092,628	3,695,147	5,348,699	283,866
Bonds payable	11,778,373	11,921,003	-	11,921,003	-	-
Notes and accounts payable	862,882	862,882	862,882	-	-	-
Other payables	2,504,875	2,504,875	2,504,875	-	-	-
Guarantee deposits received	119,435	119,435	169	119,266	-	-
Lease liabilities	1,090,183	1,331,800	124,899	112,273	293,209	801,419
	\$ <u>33,777,256</u>	35,249,549	4,828,171	16,071,438	13,264,655	1,085,285

The Group did not expect that the cash flows included in the maturity analysis could occur significantly earlier or at significantly different amounts.

(iii) Currency risk

1) Exposure to currency risk

The Group's significant exposure to foreign currency risk were as follows:

	Sep	tember 30, 2023	3	De	cember 31, 202	22	Ser	tember 30, 20	22
	Foreign currency	Exchange rate	NT\$	Foreign currency	Exchange rate	NT\$	Foreign currency	Exchange rate	NT\$
Financial assets									
Monetary items									
USD	\$ 158,553	32.27	5,116,512	279,147	30.71	8,572,598	300,452	31.75	9,539,356
EUR	219	33.91	7,413	607	32.72	19,877	1,051	31.26	32,846
JPY	400,932	0.2162	86,682	727,741	0.2324	169,127	956,530	0.2201	210,532
GBP	11	39.23	435	11	37.09	409	11	35.53	392
HKD	59	4.123	242	59	3.938	232	59	4.044	239
RMB	66	4.42	290	323	4.41	1,423	322	4.47	1,441
SGD	1	23.53	20	1	22.88	20	1	22.21	19
		\$	5,211,594		\$	8,763,686			9,784,825
Non-monetary items									
USD	\$ 17,005	32.27	548,745	18,332	30.71	562,980	21,464	31.75	681,476
RMB	239,582	4.42	1,056,675	221,729	4.41	975,781	212,848	4.47	950,361
		\$	1,605,420		S	1,538,761		5	1,631,837
Financial liabilities									
Monetary items									
USD	\$ 246,190	32.27	7,944,551	206,821	30.71	6,351,478	209,415	31.75	6,648,922
EUR	260	33.91	8,817	226	32.72	7,395	180	31.26	5,631
JPY	782,162	0.2162	169,103	366,445	0.2324	85,162	374,954	0.2201	82,527
		\$	8,122,471		5	6,444,035		9	6,737,080
		-							

2) Sensitivity analysis

The Group's exposure to foreign currency risk arises from the translation of the foreign currency exchange gains and losses on cash and cash equivalents, notes and accounts receivable, other receivables, financial assets at fair value through profit or loss, notes and accounts payable, other payables, long-term borrowings, etc. that are denominated in foreign currency. A strengthening (weakening) 5% of appreciation (depreciation) of the TWD against the USD, EUR, GBP, JPY, HKD, RMB, SGD, etc. for the nine months ended September 30, 2023 and 2022 would have increased (decreased) the net profit (loss) after tax by \$94,485 thousand and \$149,169 thousand, respectively. The analysis assumes that all other variables remain constant.

3) Exchange gains or losses

Since the Group has many kinds of functional currency, the information on foreign exchange gains (losses) on monetary items is disclosed by total amount. For the nine months ended September 30, 2023 and 2022, foreign exchange gains (losses) (including realized and unrealized portions) amounted to \$(777,462) thousand and \$509,519 thousand, respectively.

(iv) Interest rate risk

Please refer to the attached note for the liquidity risk and the Group's interest rate exposure to its financial liabilities.

The following sensitivity analysis is based on the risk exposure to interest rates on the nonderivatives financial instruments on the reporting date. For variable rate instruments, the sensitivity analysis assumes the variable rate liabilities are outstanding for the whole year on the reporting date.

If the interest rate increases (decreases) by 0.5%, the Group's net profit (loss) after tax would have increased (decreased) by \$60,910 thousand and \$45,936 thousand for the nine months ended September 30, 2023 and 2022, respectively, all other variable factors that remain constant. This is mainly due to the Group's borrowing in floating rates.

(v) Fair value

1) Financial instrument classifications and fair values

The fair value of financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income are measured on a recurring basis. The carrying amounts and fair values of the Group's financial assets and liabilities, including the information on fair value hierarchy were, as follows; however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and lease liabilities disclosure of fair value information is not required.

Part		September 30, 2023				
Publicly traded stocks		Comming value	Loyal 1			Total
Funds and investment	Financial assets at fair value through profit or loss	Carrying value	Level 1	Level 2	Level 3	Total
Private fund	Publicly traded stocks	\$ 460,509	460,509	-	-	460,509
Private fund	Funds and investment	136,649	136,649	-	-	136,649
Subtotal assets affir value through other comprehensive incomes Succlassified on domestic and forcign markets Succlassified on domestic and forcign markets Substitution Substit	Private fund		-	-	1,427,329	
Financial assets at fair value through other comprehensive Scocks Sco	Subtotal		597,158			
Stocks listed on domestic and foreign markets \$ 2,662,981 2,662,981 .	Financial assets at fair value through other comprehensive income			:		
Non-public stocks			2.662.981	-	-	2.662.981
Subtotal Subtotal	· ·		-,,	_	405 546	
Financial assets measured at amortized cost	-		2 662 981			
Cash and cash equivalents (Note)		0,000,027	2,002,701	:	103,510	0,000,027
Notes and accounts receivables (Note) 1,206,480		\$ 6352259	_	_	_	_
Other receivables (Note) 20,194 <						
Other non-current assets (Note) 389,121 -			-	-	-	-
Subtotal Subtotal			-	-	-	-
Primarcial liabilities at fair value through profit or loss 260,587 26				 .		
Derivative financial liabilities S 260,587 - 260,587 - 260,587		5 /,908,034		 :		
Primacial liabilities measured at amortized cost Bank loans (Note) \$ 19,937,342				260 505		260 505
Bank loans (Note)		\$ 260,587		260,587	=	260,587
Bonds payable (Note) 5,272,178						
Notes and Accounts payable (Note) 1,590,315 .			-	-	-	-
Other payables (Note) 2,220,754 - - - Guarantee deposits received (Note) 120,170 - - - Lease liabilities (Note) 972,585 - - - - Subtotal Subtotal Embers 11, 2022 Financial assets at fair value through profit or loss Publicly traded stocks \$ 301,109 - - 301,109 Funds and investment 111,296 111,296 - 1,369,943 1,369,943 - - 111,296 111,296 111,296 - 1,369,943 1,361,			-	-	-	-
Guarantee deposits received (Note) 120,170 - 301,109 - - - 301,109 - - - 301,109 - - - 301,109 - - - 301,109 - - - 301,109 - - - 101,109 - - - 301,109 - - - 101,109 - - - 101,109 - - - 101,109 - - <th< td=""><td></td><td></td><td>-</td><td>-</td><td>-</td><td>-</td></th<>			-	-	-	-
Lease liabilities (Note) 972,585 - 301,109 - - - 301,109 - - - 301,109 - - - 301,109 - - - 301,109 - - - 301,109 - - - 301,109 - - - 301,109 - - - 301,109 - - - 301,109 - - - 301,109 - - - 301,109 - - - 301,109 - - - 1369,943 1,369,943 - - - - -		2,220,754	-	-	-	-
Subtotal Subtotal	Guarantee deposits received (Note)	120,170	-	-	-	-
Publicity traded stocks \$ 301,109 301,109 - 1,369,943 1,369,943 1,369,943 1,369,943 1,361,612	Lease liabilities (Note)	972,585			<u> </u>	
Publicly traded stocks \$ 301,109 301,109 - - 301,109	Subtotal	\$ 30,113,344				
Publicly traded stocks \$ 301,109 301,109 - - 301,109			De	ecember 31, 2022		
Publicly traded stocks \$ 301,109 301,109 - - 301,109						
Publicly traded stocks \$ 301,109 301,109 - - 301,109 Funds and investment 111,296 111,296 - - 111,296 Private fund 1,369,943 - - 1,369,943 1,369,943 Subtotal \$ 1,782,348 412,405 - 1,369,943 1,782,348 Financial assets at fair value through other comprehensive income - - 1,369,943 1,782,348 Financial assets at fair value through other comprehensive income - - 1,361,612 - - 1,361,612 Non-public stocks 480,320 - - 480,320 480,320 480,320 480,320 480,320 1,841,932 1,361,612 - 480,320 1,841,932 1,361,612 -	Financial assets at fair value through profit or loss	Carrying value	Level 1	Level 2	Level 3	Total
Funds and investment 111,296 111,296 111,296 Private fund 1,369,943 1,369,943 1,369,943 Subtotal \$ 1,782,348 412,405 - 1,369,943 1,782,348 Financial assets at fair value through other comprehensive income Stocks listed on domestic and foreign markets \$ 1,361,612 1,361,612 1,361,612 Non-public stocks 480,320 480,320 480,320 Subtotal \$ 1,841,932 1,361,612 - 480,320 1,841,932 Financial assets measured at amortized cost Cash and cash equivalents (Note) \$ 10,379,712	= -	\$ 201.100	201 100			201 100
Private fund 1,369,943 - - 1,369,943 1,369,943 Subtotal \$ 1,782,348 412,405 - 1,369,943 1,782,348 Financial assets at fair value through other comprehensive income Stocks listed on domestic and foreign markets \$ 1,361,612 - - - 1,361,612 Non-public stocks 480,320 - - 480,320 480,320 Subtotal \$ 1,841,932 1,361,612 - 480,320 1,841,932 Financial assets measured at amortized cost Cash and cash equivalents (Note) \$ 10,379,712 - - - - - - Notes and accounts receivable (Note) 916,640 -	•			-	-	
Subtotal Subtotal			111,290	-	1 260 042	
Financial assets at fair value through other comprehensive income Stocks listed on domestic and foreign markets \$ 1,361,612				 -		
Stocks listed on domestic and foreign markets \$ 1,361,612 1,361,612 - - 1,361,612 Non-public stocks 480,320 - - 480,320 480,320 Subtotal \$ 1,841,932 1,361,612 - 480,320 1,841,932 Financial assets measured at amortized cost			412,405	:	1,369,943	1,782,348
Non-public stocks 480,320 - - 480,320 480,320 Subtotal \$ 1,841,932 1,361,612 - 480,320 1,841,932 Financial assets measured at amortized cost Cash and cash equivalents (Note) \$ 10,379,712 -						
Subtotal \$ 1,841,932 1,361,612 - 480,320 1,841,932 Financial assets measured at amortized cost Cash and cash equivalents (Note) \$ 10,379,712 Notes and accounts receivable (Note) 916,640 Other receivables (Note) 56,976 Other non-current assets (Note) 417,950 Subtotal \$ 11,771,278 Financial liabilities at fair value through profit or loss	ě		1,361,612	-	-	
Financial assets measured at amortized cost Cash and cash equivalents (Note) \$ 10,379,712				- -		
Cash and cash equivalents (Note) \$ 10,379,712 - - - Notes and accounts receivable (Note) 916,640 - - - Other receivables (Note) 56,976 - - - Other non-current assets (Note) 417,950 - - - Subtotal \$ 11,771,278 - - - - Financial liabilities at fair value through profit or loss		\$ 1,841,932	1,361,612	 :	480,320	1,841,932
Notes and accounts receivable (Note) 916,640 - - - - Other receivables (Note) 56,976 - - - - Other non-current assets (Note) 417,950 - - - - Subtotal \$ 11,771,278 - - - - - Financial liabilities at fair value through profit or loss						
Other receivables (Note) 56,976 - - - - Other non-current assets (Note) 417,950 - - - - Subtotal \$ 11,771,278 - - - - Financial liabilities at fair value through profit or loss			-	-	-	-
Other non-current assets (Note) 417,950 -			-	-	-	-
Subtotal \$ 11,771,278		56,976	-	-	-	-
Financial liabilities at fair value through profit or loss	Other non-current assets (Note)	417,950		 .	 _	<u> </u>
	Subtotal	\$ <u>11,771,278</u>			<u>-</u>	-
Derivative financial liabilities \$ 449,261 - 449,261 - 449,261	Financial liabilities at fair value through profit or loss					
	Derivative financial liabilities	\$ 449,261		449,261	<u>-</u>	449,261

			Dec	ember 31, 2022		
	Ca	rrying value	Level 1	Fair va	Level 3	Total
Financial liabilities measured at amortized cost		arying value	<u> </u>	Ecvel 2	Levero	10001
Bank loans (Note)	\$	17,601,445	-	-	-	-
Bonds payable (Note)		10,669,555	-	-	-	-
Notes and accounts payable (Note)		1,016,716	-	-	-	-
Other payables (Note)		2,362,432	-	-	-	-
Guarantee deposits received (Note)		119,299	-	-	-	-
Lease liabilities (Note)	_	1,028,402	<u> </u>		<u> </u>	
Subtotal	\$	32,797,849	<u> </u>	<u> </u>		<u>-</u>
			Sept	tember 30, 2022		
			•	Fair va		
Financial assets at fair value through profit or loss	_Ca	rrying value	Level 1	Level 2	Level 3	Total
Stocks listed on domestic markets	\$	290,366	290,366			290,366
Funds and investment	Þ	587,762	587,762	-	-	587,762
Private fund		1,461,865	387,702	-	1,461,865	1,461,865
Subtotal	<u> </u>	2,339,993	878,128		1,461,865	2,339,993
Financial assets at fair value through other comprehensive incomprehensive inc	*=	2,337,773	676,126	 _	1,401,003	2,337,773
Stocks listed on domestic and foreign markets	\$ \$	1,126,598	1,126,598	_	_	1,126,598
Non-public stocks	Ψ	536,462	1,120,370	_	536,462	536,462
Subtotal	\$	1,663,060	1,126,598		536,462	1,663,060
Financial assets measured at amortized cost	=	1,000,000	1,120,000	=======================================		1,000,000
Cash and cash equivalents (Note)	\$	10,880,336	_	_	_	_
Notes and accounts receivable (Note)	Ψ	1,312,226	-	-	_	-
Other receivables (Note)		45,839	-	-	-	-
Other non-current assets (Note)		506,281	-	-	_	-
Subtotal	\$	12,744,682				
Financial liabilities at fair value through profit or loss						
Derivative financial liabilities	\$	597,050	-	597,050	-	597,050
Financial liabilities measured at amortized cost	=	=======================================				
Bank loans (Note)	\$	17,421,508	-	-	-	-
Bonds payable (Note)		11,778,373	-	-	-	-
Notes and accounts payable (Note)		862,882	-	-	-	-
Other payables (Note)		2,504,875	-	-	-	-
Guarantee deposits received (Note)		119,435	-	-	-	-
Lease liabilities (Note)		1,090,183	<u> </u>	<u> </u>		
Subtotal	\$	33,777,256	-	-	-	-

Note: The information on fair value is not disclosed since the carrying amount is a reasonable approximation of fair value.

2) Valuation techniques of financial instrument not valued at fair value

The valuation techniques of the Group's financial instruments not valued at fair value by using the methods and assumptions are as follows:

• Financial assets measured at amortized cost and financial liabilities measured at amortized cost.

If recent transaction prices or market maker quotes are available, the fair value is based on such information. If there is no quoted market price available, the fair value is determined by using valuation techniques and calculated as the present value of the estimated cash flows.

- 3) Valuation techniques of financial instruments valued at fair value
 - a) Non-derivative instruments

The fair value of financial assets and liabilities traded in an active market is based on the quoted market prices. The quotation, which is published by the main exchange center or that which was deemed to be a public bond by the Treasury Bureau of Central Bank, is included in the fair value of the listed securities instruments and the debt instruments in active markets with open bid.

A financial instrument is regarded as the quoted price in an active market if the quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency; and if those prices represent the actual and regularly occurring market transactions on an arm's length basis. Otherwise, the market is deemed to be inactive. Normally, a market is considered to be inactive when:

- The bid-ask spread is increasing; or
- The bid-ask spread varies significantly; or
- There has been a significant decline in trading volume.

When the financial instrument of the Group is traded in an active market, its fair value is illustrated by the category and nature as follows:

- Financial assets and liabilities with standard terms and conditions and traded in an active market, for example, investment in stock of listed companies: the fair value is based on the market quoted price.
- Close-end funds with standard terms and conditions, such as money market funds; investors can require the investment trust company to redeem the fund at any time. The fair value is based on the net value of the fund.

Except for the above-mentioned financial instruments traded in an active market, the fair value is based on the valuation techniques or the quotation from the counter-party. The fair value refers to the current fair value of the other financial instruments with similar conditions and characteristics, using a discounted cash flow analysis or other valuation techniques, such as calculations of using models (for example, applicable yield curve from Taipei Exchange, or average quoted price on interest rate of commercial paper from Reuters), based on the information acquired from the market at the balance sheet date.

When the financial instrument of the Group is not traded in an active market, its fair value is determined as follows:

- The fair value is determined based on the ratio of the quoted market price of the comparative listed company and its book value per share and its sales revenue per share. Also, the fair value is discounted for its lack of liquidity in the market.
- The fair value is determined by using the asset-based approach, whose assumptions are based on the market approach, income approach, cost approach or other valuation methods according to the nature of the assets or liabilities of the subject companies.

b) Derivative instruments

The fair value is determined by using the models that are acceptable to the market participants, for example, discounted cash flow analyses or option pricing models. Forward exchange contracts are measured using quoted forward exchange rates. The fair value of structured interest derivative financial instruments is determined by using the proper option pricing models, such as Black-Scholes model, or other valuation technique, such as Monte Carlo simulation.

4) Level transfers of financial instruments

In July 2023, Gogolook Co., Ltd., which the Group holds an investment in equity shares of, listed its equity shares on a stock exchange and it is currently actively traded in the market. Because the equity shares now have published price quotation in an active market, the fair value measurement was transferred from Level 3 to Level 1 of the fair value hierarchy since the third quarter of 2023.

In April 2022, Vanchip (Tianjin) Technology Co, Ltd., which the Group holds an investment in equity shares of, listed its equity shares on a stock exchange and it is currently actively traded in the market. Because the equity shares now have published price quotation in an active market, the fair value measurement was transferred from Level 3 to Level 1 of the fair value hierarchy since the second quarter of 2022.

5) Movement of level 3

	<u>_</u> F	air value throug	h profit or loss	Fair value through other comprehensive income
		Unquoted equity		Unquoted equity
		instruments	Private fund	instruments
Balance as of January 1, 2023	\$	-	1,369,943	480,320
Total gains or losses:				
Recognized in profit and loss		-	17,856	-
Recognized in other comprehensive income	;	-	-	50,569
Purchased		-	61,351	720
Capital reduction		-	(21,821)	(18,000)
Transfers out of level 3		-	-	(109,624)
Effect of changes in foreign exchange rates	_	_		1,561
Balance as of September 30, 2023	\$_		1,427,329	405,546
Balance as of January 1, 2022	\$	380,417	1,442,016	680,342
Total gains or losses:				
Recognized in profit and loss		4,927	(35,869)	-
Recognized in other comprehensive income	;	-	-	(110,539)
Purchased		-	64,437	-
Disposals		-	-	(19,744)
Capital reduction		-	(8,719)	(17,667)
Transfers out of level 3		(398,433)	-	-
Effect of changes in foreign exchange rates	_	13,089		4,070
Balance as of September 30, 2022	\$ _		1,461,865	536,462

The preceding gains and losses were recognized as "other gains and losses" and "unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive income". As of September 30, 2023 and 2022, the related information of the assets which were still held by the Group were as follows:

	mo	r the three of the ended tember 30, 2023	For the three months ended September 30, 2022	For the nine months ended September 30, 2023	For the nine months ended September 30, 2022
Total gains or losses					
Profit or loss (recognized as other gains and					
losses)	\$	(41,188)	(166,183)	17,856	(35,869)
Other comprehensive income (recognized as unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive					
income)		(105,686)	(65,422)	50,569	(110,539)

6) Quantified information on significant unobservable inputs (Level 3) used in fair value measurement

The Group's financial instruments that use Level 3 inputs to measure fair value include "financial assets at fair value through profit or loss – private funds" and "financial assets at fair value through other comprehensive income – equity investments."

Most of the fair value measurements categorized within Level 3 use the single and significant unobservable input. Equity investments without an active market contains multiple significant unobservable inputs. The significant unobservable inputs of the equity investments are independent from each other, as a result, there is no relevance between them.

Quantified information of significant unobservable inputs was as follows:

Item	Valuation technique	Significant unobservable inputs	Inter-relationships between significant unobservable inputs and fair value measurement
Financial assets at fair value through other comprehensive income – equity investments without an active market	 Comparable companies approach 	 Price-book ratio (as of September 30, 2023, December 31 and September 30, 2022 were 1.71~3.81, 1.58~4.05 and 1.66~4.76, respectively) Market liquidity discount rate (as of September 30, 2023, December 31 and September 30, 2022 were all 20%) 	 The higher the price-book ratio, the higher the fair value The higher the market liquidity discount rate, the lower the fair value
	Net asset value method	Net asset value	• The higher the net assets value, the higher the fair value
Financial assets at fair value through profit or loss – private fund	Net asset value method	Net asset value	• The higher the net assets value, the higher the fair value

(Continued)

7) Sensitivity analysis of reasonably possible alternative assumptions for fair value measurements in Level 3 of the fair value hierarchy

The fair value measurements of the Group's financial instruments are reasonable. However, changes in the use of valuation models or valuation variables may affect the estimations. For fair value measurements in Level 3, a fluctuation in the valuation variable by 5% would have the following effect:

					anges in fair rofit or loss	Effects of changes in fair value on other comprehensive income		
		Increase or						
September 30, 2023	Inputs	decrease	<u> </u>	<u>avorable</u>	<u>Unfavorable</u>	Favorable	<u>Unfavorable</u>	
Financial assets at fair value through profit or loss								
Private fund	Net asset value	5%	\$	71,366	(71,366)	-	-	
Financial assets at fair value through other comprehensive income								
Equity investments without an active market	Price-book ratio	5%		-	-	13,046	(13,046)	
"	Market liquidity discount rate	5%		-	-	13,046	(13,046)	
"	Net asset value	5%		-	-	7,231	(7,231)	
December 31, 2022								
Financial assets at fair value through profit or loss								
Private fund	Net asset value	5%		68,497	(68,497)	-	-	
Financial assets at fair value through other comprehensive income								
Equity investments without an active market	Price-book ratio	5%		-	-	6,611	(6,611)	
"	Market liquidity discount rate	5%		-	-	6,611	(6,611)	
"	Net asset value	5%		-	-	17,406	(17,406)	
September 30, 2022								
Financial assets at fair value through profit or loss								
Private fund	Net asset value	5%		73,093	(73,093)	-	-	
Financial assets at fair value through other comprehensive income								
Equity investments without an active market	Price-book ratio	5%		-	-	8,605	(8,605)	
n,	Market liquidity discount rate	5%		-	-	8,605	(8,605)	
"	Net asset value	5%		-	-	18,219	(18,219)	

The favorable and unfavorable effects represent the changes in fair value, and fair value is based on a variety of unobservable inputs calculated using a valuation technique. The analysis above only reflects the effects of changes in a single input, and it does not include the inter-relationships with another input.

(ab) Management of financial risk

There was no significant change in the Group's objective and policies for the management of financial risk of the consolidated financial statements for the nine months ended September 30, 2023 which compared with the consolidated financial statements Note 6(ad) for the year ended December 31, 2022.

(ac) Capital management

The Group's objective, policies and process of capital management of the consolidated financial statements for the nine months ended September 30, 2023 were the same as the consolidated financial statements for the year ended December 31, 2022. For the related information, please refer to Note 6(ae) of the consolidated financial statements for the year ended December 31, 2022.

As of September 30, 2023, December 31 and September 30, 2022, the Group's return on common equity was (1.86)%, 5.28% and 7.33%, respectively. The Group's debt ratio at the reporting date was as follows:

	September 30,	December 31,	September 30,
	2023	2022	2022
Debt ratio	47.25 %	49.10 %	49.75 %

(ad) Financing activity

Reconciliations of liabilities arising from financing activities were as follows:

			_	ľ	Non-cash changes		
	Ja	nuary 1, 2023	Cash flows	Interest expense	Others	Amortization of arranger fee of syndicated loan	September 30, 2023
Short-term borrowings	\$	-	21,556	-	-	-	21,556
Long-term borrowings		17,601,445	1,865,537	-	418,801	30,003	19,915,786
Bonds payable.		10,669,555	(4,707,788)	76,219	(765,808)	-	5,272,178
Guarantee deposit received		119,299	871	-	-	-	120,170
Lease liabilities	_	1,028,402	(80,134)	17,370	6,947		972,585
Total liabilities from financing activity	\$	29,418,701	(2,899,958)	93,589	(340,060)	30,003	26,302,275

			_	N	Non-cash changes		
	Ja	nuary 1, 2022_	Cash flows	Interest expense	Others	Amortization of arranger fee of syndicated loan	September 30, 2022
Short-term borrowings	\$	-	18,805	-	-	-	18,805
Long-term borrowings		15,992,820	536,883	-	846,551	26,449	17,402,703
Bonds payable		13,286,639	(1,247,799)	126,975	(387,442)	-	11,778,373
Guarantee deposit received		130,398	(10,963)	-	-	-	119,435
Lease liabilities (Note)	_	1,157,209	(106,591)	20,237	19,328		1,090,183
Total liabilities from financing activity	\$	30,567,066	(809,665)	147,212	478,437	26,449	30,409,499

Note: Interest expense includes capitalized interest expense transferred to construction in progress, which amounted to \$46 thousand.

(7) Related-party transactions:

(a) Names of related parties and their relationship with related parties

The followings are related parties that have had transactions with the Group during the periods covered in the consolidated financial statements:

Name of related party	Relationship with the Group
Jiangsu CM/Chainwin Agriculture Development Co., Ltd. (abbrev.	Associates
Jiangsu CM/Chainwin)	
ITEQ Corporation (abbrev. ITEQ)	Associates
Taoyuan i-Fare Charity Foundation	Other related parties

- (b) Significant transactions with related parties
 - (i) Operating expenses

The amounts of operating expenses by the Group from related parties were as follows:

	For the	three	For the three	For the nine	For the nine
	months	ended	months ended	months ended	months ended
	Septemb	er 30,	September 30,	September 30,	September 30,
	202	23	2022	2023	2022
Other related parties	\$	1,116	_	5,457	

(ii) Guarantee

As of September 30, 2023, December 31, and September 30, 2022, Chainwin Cayman had provided a guarantee for loans amounting to US\$7,350 thousand (\$237,185 thousand, \$225,719 thousand and \$233,363 thousand, respectively) to its associate, Jiangsu CM/Chainwin.

(iii) Leases

The Group leased the office and factories to its associate, ITEQ, and the rent income received monthly is based on the nearby office and factories rental rates. The amount of rent income is \$7,717 thousand, \$7,375 thousand, \$23,150 thousand and \$22,127 thousand for the three months and nine months ended September 30, 2023 and 2022. The preceding rent payment has been received. The guarantee deposits received amounted to \$110,000 thousand as of September 30, 2023, December 31, and September 30, 2022.

(c) Transactions with key management personnel

Key management personnel compensation was comprised as below:

	mo	r the three nths ended tember 30, 2023	For the three months ended September 30, 2022	For the nine months ended September 30, 2023	For the nine months ended September 30, 2022
Short-term employee benefits	\$	40,667	41,286	117,022	233,139
Post-employment benefits		311	315	938	945
	\$	40,978	41,601	117,960	234,084

(8) Pledged assets:

The carrying amounts of pledged assets were as follows:

Other non-current assets	Pledged to secure	Sep	otember 30, 2023	December 31, 2022	September 30, 2022
Other non-current assets	Land, plant, and dormitory lease guarantee	\$	23,556	36,301	36,733
Other non-current assets	Bank borrowings		194,009	120,658	219,131
Other non-current assets	Gas deposits		4,700	4,700	4,700
Other non-current assets	Customs guarantee with interest		20,981	20,736	20,786
Other non-current assets	Seized funds and court security deposits		47,342	86,866	75,214
Property, plant and	Bank borrowings				
equipment			3,575,704	2,154,811	2,177,104
Total		\$	3,866,292	2,424,072	2,533,668

(9) Commitments and contingencies:

(a) Contingencies: None.

(b) Commitment:

(i) The unrecognized commitment of acquisition of plant expansion and machinery equipment was as follows:

The unrecognized amount	Sep	otember 30, 2023	December 31, 2022	September 30, 2022	
The unrecognized amount	\$	4,648,460	5,891,406	6,756,460	

(ii) The unused letters of credit was as follows:

	September 30, 2023	December 31, 2022	September 30, 2022
The unused letters of credit	<u> </u>	5,967	4,584

(10) Losses due to major disasters: None.

(11) Subsequent events:

The Company has repurchased the first issued unsecured overseas convertible bonds in 2020 at the principle amount of US\$20,000 thousand after the end of reporting period.

(12) Other:

(a) The followings were the summary statement of employee benefits, depreciation and amortization expenses by function:

	For the three r	nonths ended S 2023	eptember 30,	For the three months ended September 30, 2022						
	Classified as operating costs	Classified as operating expenses	Total	Classified as operating costs	Classified as operating expenses	Total				
Employee benefits										
Salaries	516,338	238,225	754,563	462,785	220,396	683,181				
Labor and health insurance	52,236	18,300	70,536	59,818	21,209	81,027				
Pension	25,064	10,805	35,869	25,520	10,693	36,213				
Director remuneration	-	3,060	3,060	-	7,030	7,030				
Others	25,286	6,536	31,822	25,620	7,126	32,746				
Depreciation	977,820	204,166	1,181,986	849,835	188,008	1,037,843				
Amortization	9,601	20,142	29,743	8,256	26,677	34,933				

	For the nine n	nonths ended Se 2023	eptember 30,	For the nine months ended September 30, 2022						
	Classified as operating costs	Classified as operating expenses	Total	Classified as operating costs	Classified as operating expenses	Total				
Employee benefits										
Salaries	1,572,942	718,949	2,291,891	1,861,427	818,905	2,680,332				
Labor and health insurance	166,301	57,470	223,771	195,740	62,003	257,743				
Pension	76,146	33,081	109,227	81,100	32,468	113,568				
Director remuneration	-	8,012	8,012	-	43,117	43,117				
Others	78,034	19,513	97,547	84,434	22,839	107,273				
Depreciation	2,800,358	630,473	3,430,831	2,685,169	461,572	3,146,741				
Amortization	25,295	63,650	88,945	24,789	82,516	107,305				

(b) Seasonality of operations:

The Group's operations were not affected by seasonality or cyclicality factors.

(13) Other disclosures:

(a) Information on significant transactions:

The following were the information on significant transactions required by the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" for the Group for the nine months ended September 30, 2023:

- (i) Loans to other parties: Please refer to schedule A.
- (ii) Guarantees and endorsements for other parties: Please refer to schedule B.
- (iii) Securities held as of September 30, 2023 (excluding investment in subsidiaries, associates and joint ventures): Please refer to schedule C.
- (iv) Individual securities acquired or disposed of with accumulated amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital: Please refer to schedule D.
- (v) Information on acquisition of real estate with purchase amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital: Please refer to schedule E.
- (vi) Information on disposal of real estate with amounts exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital: None.
- (vii) Information regarding related-parties purchases and/or sales with amounts exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital: Please refer to schedule F.

- (viii) Information regarding receivables from related-parties exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital: Please refer to schedule G.
- (ix) Information regarding trading in derivative financial instruments: Please refer to Note 6(b).
- (x) Business relationships and significant inter-company transactions: Please refer to schedule H.
- (b) Information on investments: Please refer to schedule I.
- (c) Information on investment in mainland China: Please refer to schedule J.
- (d) Information on major shareholders: Please refer to schedule K.

(14) Segment information:

(a) General information:

The Group's reportable segment are the foundry segment, and agriculture technology segment. The segments engages separately in researching, developing, manufacturing, selling of GaAs wafers and researching and developing hog farming technology and trading, etc., respectively.

Other operating segments are mainly engaged in investment activities and testing service gene chip, which do not exceed the quantitative thresholds to be reported.

(b) Profit or loss (including reportable segment specific revenue and expenses), segment assets, segment liabilities, and their measurement and reconciliations:

The reportable amount is same as that in the report used by the operating decision maker and the operating segment accounting policies are same as the ones described in Note 4 "significant accounting policies" were as follows:

For the three months ended September 30, 202	23	Foundry	Agriculture technology	Others	Reconciliation and elimination	Total
Revenue:						
Revenue from external customers	\$_	4,084,667	176,978	(96,635)		4,165,010
Interest expenses	\$	42,454	129,668	1,588		173,710
Depreciation and amortization	\$	999,885	203,851	7,993		1,211,729
Share of profit (loss) of associates and joint ventures accounted for using equity method	\$_	32,155	(13,961)	(3,528)		14,666
Reportable segment profit or loss	\$	523,617	(281,352)	(172,193)		70,072
Assets:	_					
Capital expenditures in non-current assets	\$_	1,814,426	93,477	450		1,908,353

For the three months ended September 30, 2022 Revenue:	2	Foundry	Agriculture technology	Others	Reconciliation and elimination	Total
Revenue from external customers	\$	3,834,355	92,075	(17,688)	_	3,908,742
Interest expenses	\$ \$	46,970	36,091	1,647	_	84,708
Depreciation and amortization	\$ \$	973,138	91,052	8,586		1,072,776
Share of profit (loss) of associates and joint ventures accounted for using equity method	\$	43,912	9,447	(47,176)		6,183
Reportable segment profit or loss	\$	205,954	(164,839)	(241,556)	-	(200,441)
Assets:	_					
Capital expenditures in non-current assets	\$_	1,263,326	650,538	4,566		1,918,430
For the nine months ended September 30, 2023		Foundry	Agriculture technology	Others	Reconciliation and elimination	Total
Revenue:						
Revenue from external customers	\$ _	10,296,118	440,885	231,459		10,968,462
Interest expenses	\$ _	136,675	342,209	4,791		483,675
Depreciation and amortization	\$_	2,923,387	571,104	25,285		3,519,776
Shares of profit (loss) of associates and joint ventures accounted for using equity method	\$_	59,005	(82,951)	8,733		(15,213)
Reportable segment profit or loss	\$_	133,493	(855,027)	26,591		(694,943)
Assets:	_					
Capital expenditures in noncurrent assets	\$_	2,697,163	334,042	6,091		3,037,296
			Agriculture		Reconciliation and	T. ()
For the nine months ended September 30, 2022 Revenue:		Foundry	technology	Others	elimination	Total
Revenue from external customers	\$	14,379,804	288,648	134,608	-	14,803,060
Interest expenses	\$	146,557	95,007	4,997		246,561
Depreciation and amortization	\$	2,960,966	267,866	25,214		3,254,046
Shares of profit (loss) of associates and joint ventures accounted for using equity method	\$	235,333	(21,123)	45,045		259,255
Reportable segment profit or loss	\$	2,370,678	(689,534)	(218,133)		1,463,011
Assets:	=					
Capital expenditures in noncurrent assets	\$_	4,831,075	1,432,467	8,069		6,271,611

For the three months and nine months ended September 30, 2023 and 2022, reportable segment profit or loss excludes non-operating income and expenses, amounting to \$(114,268) thousand, \$499,769 thousand, \$(266,553) thousand and \$495,755 thousand, respectively.

Schedule A Loans to other parties:

(In thousands of Dollar	rs
-------------------------	----

Number (Note 1)	Name of lender	Name of borrower	Account name	Related party	other parties du	ring	Ending balance (Note 2)	Actual amount drawn down	Interest rate	Purposes of fund financing for the borrower		Reasons for short-term financing	Allowance for bad debts		ateral	Individual funding loan limits (Note 4) (Note 5)	Maximum limit of fund financing (Note 4) (Note 5)	Remark
					the period (Note	(2)				(Note 3)				Item	Value	(Note 6)	(Note 6)	
1	Chainwin Biotech and Agrotech	Jiangsu Chainwin Kang Yuan Agricultural	Other receivables	Y	968,	100	645,400	645,400	1%	2	-	Working	-	None	-	Net equity 20%=	Net equity 40%=	(Note 8)
	(Cayman Islands) Co., Ltd.	Development Co., Ltd.			(USD 30,0	00)((USD 20,000)	(USD 20,000)				Capital				1,494,324	2,988,648	
1	Chainwin Biotech and Agrotech	Jiangsu Win Yield Agriculture Development	Other receivables	Y	645,	400	-	-	1%	2	-	Working	-	None	-	Net equity 20%=	Net equity 40%=	(Note 8)
	(Cayman Islands) Co., Ltd.	Co., Ltd.			(USD 20,0	00)						Capital				1,494,324	2,988,648	
2	Jiangsu Chainwin Agriculture and	Jiangsu Win Shine Agriculture Development	Other receivables	Y	17,	186	-	-	0%	2	-	Working	-	None	-	Net equity 100%=	Net equity 200%=	(Note 8)
	Animal Technology Co., Ltd.	Co., Ltd.			(RMB 3,8	93)						Capital				958,724	1,917,449	
3	Jiangsu Win Honor Management	Jiangsu Win Yield Agriculture Development	Other receivables	Y	309,	147	-	-	1%	2	-	Working	-	None	-	Net equity 110%=	Net equity 200%=	(Note 8)
	Technology Co., Ltd.	Co., Ltd.			(USD 9,5	80)						Capital				326,081	592,876	

Note 1: Company numbering as follows:

Issuer - 0

Investee starts from 1

Note 2: The credit amount to lending.

Note 3: Purposes of lending were as follows:

- 1. Business relationship
- 2. Short-term financing
- Note 4: Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s operating procedures of financing to other parties:
 - 1. The loan limit to an individual party:(1) the total amount for lending to a company having business relationship with Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. shall not exceed their previous or current's total purchasing or sales amount (whichever is higher).
 - (2) the total amount for lending to a company having short-term funding needs shall not exceed 20% of Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s equity based on its most recent audited or reviewed financial statements by a certified accountant.
 - 2. The maximum loans to other parties limit provided by Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. to other parties should not exceed 40% of its equity based on its most recent audited or reviewed financial statements by a certified accountant.
- Note 5: Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.'s operating procedures of financing to other parties:
 - 1. The loan limit to an individual party:(1) the total amount for lending to a company having business relationship with Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd. shall not exceed their previous or current's total purchasing or sales amount (whichever is higher).
 - (2) the total amount for lending to a company having short-term funding needs shall not exceed 20% of Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd. 's equity based on its most recent audited or reviewed financial statements by a certified accountant.
 - 2. The maximum loans to other parties limit provided by Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd. to other parties should not exceed 40% of its equity based on its most recent audited or reviewed financial statements by a certified accountant.
 - 3. The fund lending to Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s non-Taiwan subsidiaries (between subsidiaries) having, directly or indirectly, 100% of the voting rights; or the fund lending to the parent company, Chainwin Biotech and Agrotech (Cayman Islands)

 Co., Ltd., (subsidiary-to-parent), should not be restricted by the above limitations; however, the maximum limit for an individual party should not exceed 100% of Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.'s equity.
- Note 6: Jiangsu Win Honor Management Technology Co., Ltd. 's operating procedures of financing to other parties:
 - 1. The loan limit to an individual party: (1) the total amount for lending to a company having business relationship with Jiangsu Win Honor Management Technology Co., Ltd. shall not exceed their previous or current's total purchasing or sales amount (whichever is higher).
 - (2) the total amount for lending to a company having short-term funding needs shall not exceed 20% of Jiangsu Win Honor Management Technology Co., Ltd.'s equity based on its most recent audited or reviewed financial statements by a certified accountant.
 - 2. The maximum loans to other parties provided by Jiangsu Win Honor Management Technology Co., Ltd. should not exceed 40% of its equity based on its most recent audited or reviewed financial statements by a certified accountant.
 - 3. The fund lending to Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s non-Taiwan subsidiaries (between subsidiaries) having, directly or indirectly, 100% of the voting rights; or the fund lending to the parent company, Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd., (subsidiary-to-parent), should not be restricted by the above limitations; however, the maximum limit for an individual party should not exceed 110% of Jiangsu Win Honor Management Technology Co., Ltd.'s equity, and the total amount should not exceed 200% of Jiangsu Win Honor Management Technology Co., Ltd.'s equity.
- Note 7: The aforementioned amount was translated at the exchange rate on the balance sheet date from USD to TWD and RMB to USD for TWD 32.27 and USD 0.1368, respectively.
- Note 8: The amount of the transaction had been offset in the consolidated financial statements.

Schedule B Guarantees and endorsements for other parties:

(In thousands of Dollars)

		Counter-party of guarantee and endorser	nent	Limitation on		D.1 . C			Ratio of				
Number (Note 1)	Name of guarantor	Name	Relationship with the Company (Note 2)	amount of guarantees and endorsements for a specific enterprise (Note 3)(Note 4)	Highest balance of guarantees and endorsements during the period (Note 3)	Balance of guarantees and endorsements as of reporting date	Actual usage amount	Property pledged for guarantees and endorsements (Amount)	accumulated amounts of guarantees and endorsements to net worth of the latest financial statements	Maximum amount for guarantees and endorsements (Note 3)(Note 4)	Parent company endorsements/ guarantees to subsidiary (Note 6)	Subsidiary endorsements/ guarantees to parent company (Note 6)	Endorsements/ guarantees to the companies in mainland China (Note 6)
0	The Company	Chainwin Biotech and Agrotech (Cayman Islands)	2	16,661,662	2,132,402	2,132,402	1,613,500	-	6.40%	Net equity 50%=	Y	-	-
		Co., Ltd.								16,661,662			
0	"	Jiangsu Chainwin Kang Yuan Agricultural	2	16,661,662	2,180,420	2,180,420	1,936,200	-	6.54%	Net equity 50%=	Y	-	Y
		Development Co., Ltd.								16,661,662			
0	"	Jiangsu Win Yield Agriculture Development	2	16,661,662	3,671,810	3,671,810	3,549,700	-	11.02%	Net equity 50%=	Y	-	Y
		Co., Ltd.								16,661,662			
0	//	Jiangsu Chainwin Agriculture and Animal	2	16,661,662	1,604,787	1,604,787	1,452,150	-	4.82%	Net equity 50%=	Y	-	Y
		Technology Co., Ltd.								16,661,662			
0	//	Jiangsu Win Fortune Agriclture	2	16,661,662	30,527	30,527	-	-	0.09%	Net equity 50%=	Y	-	Y
		Development Co., Ltd.								16,661,662			
0	//	Jiangsu Win Boutique Agriculture	2	16,661,662	30,527	30,527	-	-	0.09%	Net equity 50%=	Y	-	Y
		Development Co. Ltd.								16,661,662			
0	//	Jiangsu Win Sunlight Agriculture	2	16,661,662	30,527	30,527	-	-	0.09%	Net equity 50%=	Y	-	Y
		Development Co. Ltd.								16,661,662			
1		Jiangsu CM/Chainwin Agriculture	6	2,241,486	237,185	237,185	-	-	3.17%	Net equity 50%=	-	-	Y
		Development Co., Ltd.		(USD 69,460)	(USD 7,350)					3,735,811			
1		Jiangsu Chainwin Kang Yuan Agricultural	2	2,241,486	145,215	58,086	21,556	64,540	0.78%	Net equity 50%=	-	-	Y
		Development Co., Ltd.		(USD 69,460)	(USD 4,500)	(USD 1,800)	(RMB 668)	(USD 2,000)		3,735,811			

Note 1: Company numbering as follows:

- 1. Issuer-0
- 2. Investee starts from 1
- Note 2: The 7 types of relationship between the guarantee and the guarantor were as follows:
 - 1. For entities the guarantor has business transaction with.
 - 2. For entities in which the guarantor, directly or indirectly, owned more than 50% of their shares.
 - 3. For entities who owned, directly or indirectly, more than 50% in total of the guarantor's shares.
 - 4. For entities in which the guarantor, directly or indirectly, owned more than 90% of their shares.
 - 5. Fulfillment of contractual obligation by providing mutual endorsements and guarantees for peer or joint builders in order to undertake a construction project.
 - 6. For entities who are guaranteed and endorsed by all capital contributing shareholders in proportion to each of their shareholder's percentage.
 - 7. Performance guarantee in which entities within the same industry provide among themselves joint and several securities by entering into sales agreement with each other for pre-construction project pursuant to Company Protection Act.
- Note 3: The Company's operating procedures of guarantee and endorsement were as follows:
 - 1. The guarantees and endorsements limit provided by the Company to other parties should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant. The individual guarantee amount should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.
 - 2. The guarantees and endorsements limit provided by the Company and its subsidiaries to other parties should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant. The individual guarantee amount should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.
 - 3.The Company endorses and guarantees the bank loans of its subsidiaries, including Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd., Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd., Jiangsu Win Yield Agriculture Development Co., Ltd., Jiangsu Win Fortune Agriculture Development Co., Ltd., Jiangsu Win Sunlight Agriculture Development Co. Ltd., with the total amount not exceeding US\$300,000 thousand. In the second quarter of 2023, the applications of adjustment for the individual amount of each subsidiary had been approved by the banks, without changing the overall total amount of the guarantees and endorsements during the period of each company to be based on the ratio of each borrower's balance of guarantees and endorsements to the total amount as of the reporting date.
- Note 4: Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s operating procedures of guarantee and endorsement were as follows:
 - 1. The individual guarantee amount should not exceed 30% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.
 - 2. The guarantees and endorsements limit provided by Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. to other parties should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.
- Note 5: The aforementioned amount was translated at the exchange rate on the balance sheet date from USD to TWD and RMB to USD for TWD 32.27 and USD 0.1368, respectively.
- Note 6: Fill in "Y" for those cases of provision of endorsements/ guarantees by listed parent company to subsidiary, provision by subsidiary to listed parent company, and provision to the party in mainland China.

Schedule C Securities held as of September 30, 2023 (excluding investment in subsidiaries, associates and joint ventures):

(In thousands of New Taiwan Dollars)

		D 1 .: 1:			Ending	balance		
Name of holder	Category and name of security	Relationship with the company	Account name	Shares/ Units (in thousands)	Carrying value	Percentage of ownership (%)	Fair value	Remark
The Company	Lin BioScience, Inc./Stock	None	Current financial assets at fair value through profit or loss	55	6,199	0.08	6,199	
WIN Venture Capital Corp.	Capital Money Market Fund	//	"	3,763	62,218	-	62,218	
WIN Chance Investment Corp.	Capital Money Market Fund	"	"	1,102	18,225	-	18,225	
WIN Earn Investment Corp.	Capital Money Market Fund	//	"	3,399	56,206	-	56,206	
					142,848		142,848]
The Company	MagiCapital Fund II L.P.	"	Non-current financial assets at fair value through profit or loss	-	315,034	5.81	315,034	1
n,	CDIB Capital Growth Partners L.P.	//	"	-	156,051	3.30	156,051	
n,	CDIB Capital Healthcare Ventures II L.P.	"	"	-	53,903	1.61	53,903	
n,	Fuh Hwa Oriental Fund	//	"	15,000	29,160	-	29,160	
n,	Fuh Hwa Smart Energy Fund	"	"	12,000	58,368	-	58,368	
n,	LeaSun Winion L.P.	//	"	-	34,652	12.47	34,652	
n,	NFC Fund II L.P.	//	"	-	233,711	32.44	233,711	
n,	Foryou Venture Capital L.P.	//	"	-	33,000	5.77	33,000	
n,	Renaissance Capital Limited Partnership	//	"	-	115,309	12.82	115,309	
n,	Lian Ding Capital Investments Limited Partnership	"	"	-	246,000	10.23	246,000	
n,	NFC Fund III, L.P.	//	"	-	152,141	19.90	152,141	
Win Semiconductors Cayman Islands Co., Ltd.	Vanchip (Tianjin) Technology Co., Ltd./Stock	Client	"	1,800	454,310	0.44	454,310	
					1,881,639		1,881,639]
The Company	Sino-American Silicon Products Inc./Stock	None	Non-current financial assets at fair value through other comprehensive income	529	83,053	0.09	83,053	1
n,	Inventec Solar Energy Corporation/Stock	"	"	34,000	-	10.51	-	(Note 1)
n,	CDIB Capital Creative Industries Limited/Stock	//	"	3,000	18,900	3.33	18,900	
"	MagiCap Venture Capital Co., Ltd./Preferred Stock A	//	"	543	17,359	18.28	17,359	
n,	New Future Capital Co., Ltd./Stock	"	"	8,900	81,791	15.87	81,791	
n,	Barits Biofund Inc./Stock	"	"	2,200	25,872	6.87	25,872	(Note 2)
n,	NFC I Renewable Power Co., Ltd./Stock	//	"	16,200	241,942	15.00	241,942	
n,	Gogolook Co., Ltd./Stock	//	"	3,550	569,717	11.10	569,717	
Win Semiconductors Cayman Islands Co., Ltd.	Broadcom Ltd./Stock	Client	"	75	2,010,211	0.02	2,010,211	
n,	Anokiwave Inc./Series B Preferred Stock	"	"	1,264	-	7.48	-	
WIN Venture Capital Corp.	MOAI Green Power Corporation/Stock	None	"	90	-	0.24	-	
"	Merit Biotech INC./Stock	//	"	1,320	-	2.93	-	(Note 3)
n,	Winresp INC./Stock	//	"	2,896	18,977	11.71	18,977	
Phalanx Biotech Group, Inc.	BioGenius Biotech, Co., Ltd./Stock	//	"	72	705	18.65	705]
					3,068,527		3,068,527	

Note 1: The Board of Directors of Inventec Solar Energy Corporation had declared to bankruptcy the company in December 2021. As of September 30, 2023, the company had not completed the procedure of liquidation.

Note 2: On August, 2023, the shareholders' meeting approved a resolution to rename Grand Fortune Venture Corp. to Barits Biofund Inc.

Note 3: The Board of Directors of Merit Biotech INC. had resolved to dissolve and liquidate the company in 2017. As of September 30, 2023, the company was still within the period of liquidation.

Schedule D Individual securities acquired or disposed of with accumulated amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

												(in mousands o	of New Talw	an Donars)
	Category and			Relationship	Beginning		Purchases			Sales			Ending	
Name of company	name of security	Account name	Name of counter-party	with the Company	Shares (in thousands)	Amount	Shares (in thousands)	Amount	Shares (in thousands)	Price	Cost	Gain (loss) on disposal	Shares (in thousands)	Amount
Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Win Yield Agriculture Development Co., Ltd.	Investments accounted for using equity method	-	Subsidiary	-	2,355,555	-	300,400	-	-	-	-	-	1,750,799 (Note)

Note: The amount of ending balance was calculated using the equity method. The amount of the transaction and the ending balance had been offset in the consolidated financial statements.

Schedule E Information on acquisition of real estate with purchase amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

Name of	Transaction			Relationship	If the counter-party is a related party, onship disclose the previous transfer information				References for	D of			
Name of company	Name of property	Transaction date	Transaction amount	Status of payment	Counter-party	with the Company	Owner	Relationship with the Company	Date of transfer	Amount		Purpose of acquisition	Others
The Company	Factory buildings	2021/4/6~2021/5/25		As of September 30, 2023, the price paid \$1,320,752 thousand.	Chung-Lin General Contractors, Ltd.	-	N/A	N/A	N/A	N/A	Price negotiation	Operating purpose	None
"	Factory buildings	2021/10/15	•	As of September 30, 2023, the price paid \$1,412,584 thousand.	Chung-Lin General Contractors, Ltd.	-	N/A	N/A	N/A	N/A	Price negotiation	Operating purpose	None
"	Factory buildings	2022/6/9	,	As of September 30, 2023, the price paid \$225,377 thousand.	Chung-Lin General Contractors, Ltd.	-	N/A	N/A	N/A	N/A	Price negotiation	Operating purpose	None
n	Land and buildings	2023/6/27		As of September 30, 2023, the price paid \$1,500,000 thousand.	Ofuna Develop Technology Co., Ltd.	-	N/A	N/A	N/A	N/A	Price negotiation	Operating purpose	None

Schedule F Information regarding purchase and sale from related-parties exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

N. C	D. L. L.	Nature of	Transaction details				Transactions with terms different from others		Notes / Accor			
Name of company	Related party	relationship	Purchase / Sale	Amount	Percentage of the purchases / sales	Payment terms	Unit	Payment terms	Ending balance	Percentage of total notes / accounts receivable (payable)	Remark	
Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Jiangsu Win Yield Agriculture Development Co., Ltd.	Affiliate	Purchase	107,499	30.43%	Payment term 30 days	-	-	(59,512)	47.33%	(Note)	
Jiangsu Win Yield Agriculture Development Co., Ltd.	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Affiliate	Sales	(107,499)	40.26%	Payment term 30 days	-	-	59,512	98.62%	(Note)	

Note: The amount of the transaction had been offset in the consolidated financial statements.

Schedule G Information regarding receivables from related-parties exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

Name of company	Name of counter-party	Relationship	Ending	Turnover	0	verdue	Amounts received	Allowances	Remark
Name of company	Name of counter-party	Relationship	balance	rate	Amount	Action taken	in subsequent period	for bad debts	Remark
Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Affiliate	648,192	(Note 1)	-	-	-	-	(Note 2)
Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	Affiliate	1,459,004	(Note 1)	-	-	-	-	(Note 2)

Note 1: The ending balance was other receivables, which was not applicable for the calculation of turnover rate.

Note 2: The amount of the transaction had been offset in the consolidated financial statements.

Schedule H Business relationships and significant inter-company transactions:

(In thousands of New Taiwan Dollars)

NI - 1			Nature of	Intercompany transactions					
Number (Note 1)	Name of company	Name of counter-party	relationship (Note 2)	Account name	Amount (Note 3) Trading terms		Percentage of the consolidated net revenue or total assets		
1	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	3	Other receivables due from related parties	648,192	no difference with non-related parties	0.98%		
2	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	3	Other payables due to related parties	648,192	no difference with non-related parties	0.98%		
1	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	3	Other receivables due from related parties	1,459,004	no difference with non-related parties	2.21%		
3	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	3	Other payables due to related parties	1,459,004	no difference with non-related parties	2.21%		
2	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Jiangsu Win Yield Agriculture Development Co., Ltd.	3	Purchase	107,499	no difference with non-related parties	0.98%		
4	Jiangsu Win Yield Agriculture Development Co., Ltd.	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	3	Sales	107,499	no difference with non-related parties	0.98%		

Note 1: Company numbering as follows:

Parent company – 0

Subsidiary starts from 1

Note 2: The numbering of the relationship between transaction parties as follows:

Parent company to subsidiary -1

Subsidiary to parent company – 2

Subsidiary to subsidiary – 3

Note 3: The amount of the transaction had been offset in the consolidated financial statements.

Schedule I Information on investments:

The following is the information on investees as of September 30, 2023 (excluding information on investees in mainland China):

(In thousands of New Taiwan Dollars) The ending balance at this period Original investment amount Net income Investment Name of investor Main businesses and products The ending balance Name of investee Location The ending balance Remark Shares (losses) Carrying Percentage of ownership income (losses) (in thousands) value of investee at the beginning at the end WIN SEMI. USA, INC. The Company California USA Marketing 8,203 8,203 1,000 100.00% (12,809)(5,594)(5,594)(Note 1) Win Semiconductors Cayman Cayman Islands 11,127,774 376,600 Investment activities 11,127,774 100.00% 8,734,535 (1,354,189)(1,354,189) (Note 1) Islands Co., Ltd. WIN Venture Capital Corp. Investment activities 1,040,000 1,040,000 104,000 100.00% 1,069,716 6,481 (Note 1) 6,481 Taiwan Researching, manufacturing and selling of high-density Phalanx Biotech Group, Inc. 1,079,169 53,427 73.67% 448,744 (109,659)(80,781) Taiwan 1,079,169 (Note 1) gene chips and testing service WIN Chance Investment Corp. Investment activities 830,000 830,000 87,350 100.00% 918,065 7,138 7,138 (Note 1) Taiwan 4,058 Investment activities 58,000 478,408 4,058 WIN Earn Investment Corp. Taiwan 580,000 580,000 100.00% (Note 1) 6,120,993 ITEQ Corporation Taiwan Manufactures and sells mass lamination boards, 6,120,993 65,409 18.02% 7,769,786 350,195 59,005 copper-clad laminates, prepreg, and electronic components WIN Venture Capital Corp. Phalanx Biotech Group, Inc. Taiwan Researching, manufacturing and selling of high-density 39,600 39,600 1,116 1.54% 26,779 (109,659)(Note 2) (Note 1) gene chips and testing service 8,767 2.42% ITEQ Corporation Manufactures and sells mass lamination boards, 952,396 952,396 961,894 350,195 (Note 2) Taiwan copper-clad laminates, prepreg, and electronic components British Virgin 49.30% Win Semiconductors Cayman Rainbow Star Group Limited Investment activities 62,920 62,920 38 36,948 (19,874)(Note 2) Islands Co., Ltd. Islands nvestment activities Chainwin Biotech and Agrotech Cayman Islands 10,905,959 10,905,959 185,054 81.23% 6,202,656 (1,832,007)(Note 2) (Note 1) (Cayman Islands) Co., Ltd. Chainwin Biotech and Agrotech Investment activities 500 12,236 Win Lux Biotech (Cayman Islands) Cayman Islands 15,010 15,010 100.00% (22)(Note 2) (Note 1) Cayman Islands) Co., Ltd. Co., Ltd. i-Chainwin Technology Co., Ltd. 100.00% Taiwan Information software services 220,000 220,000 22,000 128,628 (10,594)(Note 2) (Note 1) Win Lux Biotech Co., Ltd. Taiwan Biotechnology services and pharmaceutical testing 250,000 100,000 25,000 100.00% 112,935 (55,008)(Note 2) (Note 1) Phalanx Biotech Group, Inc. Phalanx Biotech Limited Investment activities 12,125 100.00% Hong Kong 18,275 4,415 (3,351)(Note 2) (Note 1) Selling of high-density gene chip and testing service 2,550 PhalanxBio, Inc. 208,110 208,110 100.00% USA (Note 2) (Note 1) 74,310 Guzip Biomarkers Corporation Taiwan Development and sales of test reagents for endometrial cancer 81,727 81,727 14,238 100.00% 1,396 (Note 2) (Note 1) WIN Chance Investment Corp. 350,195 ITEQ Corporation Taiwan Manufactures and sells mass lamination boards 832,945 832,945 7,935 copper-clad laminates, prepreg, and electronic components WIN Earn Investment Corp. 4,230 1.17% ITEQ Corporation Taiwan 568,005 568,005 422,356 350,195 (Note 2)

Note 1: The amount of the transaction had been offset in the consolidated financial statements.

Note 2: The share of profit (loss) of the investee company is not reflected herein as such amount is already included in the share of profit (loss) of the investor company.

Schedule J Information on investment in mainland China:

(i) The names of investees in mainland China, the main businesses and products, and other information:

(In thousands of New Taiwan Dollars)

Main businesses and products	Total amount of paid-in capital	Method of investment	Accumulated outflow of investment from Taiwan at the	Investment t	flows	Accumulated outflow of investment from Taiwan at the	Net income (losses) of the investee	Direct/Indirect percentage of ownership by the	Investment income (losses)	Carrying value at the end of this period	Accumulated remittance of earnings in current	Remark
•			beginning of this year	ar Outflow Inflo	Inflow	September 30, 2023		Company	(Note 5)(Note 7)	(Note 6)	period	
Developing hog farming technology	3,728,267	(Note 1)	3,309,022	-	-	3,309,022	(487,417)	81.23%	(487,417)	1,735,316	-	(Note 11)
Farm feed developing and trading	1,314,369	(Note 1)	1,291,505	-	-	1,291,505	(184,654)	81.23%	(184,654)	958,725	-	(Note 11)
Developing hog farming technology	2,059,210	(Note 1)	1,122,874	-	-	1,122,874	(169,288)	39.80%	(82,951)	602,365	-	
and trading												
Developing hog farming technology	610,094	(Note 4)	651,142	-	-	651,142	(61,243)	81.23%	(61,243)	234,729	-	(Note 11)
and trading												
Developing hog farming technology	-	(Note 1)	149,664	-	-	149,664	-	-	-	-	-	(Note 9)
and trading												
Developing hog farming technology	72,313	(Note 3)	41,009	-	-	41,009	13	81.23%	13	8,359	-	(Note 11)
and trading												
Developing hog farming technology	2,655,955	(Note 1)	2,160,535	300,400	-	2,460,935	(582,284)	81.23%	(582,284)	1,750,799	-	(Note 11)
Logistics management service	345,130	(Note 1)	85,170	-	-	85,170	(15,966)	81.23%	(15,966)	305,198	-	(Note 11)
Developing hog farming technology	288,100	(Note 4)	-	-	-	-	(15,489)	81.23%	(15,489)	255,927	-	(Note 11)
and trading	·						, , ,		, , ,			
Developing hog farming technology	288,100	(Note 4)	86,430	-	-	86,430	(7,084)	81.23%	(7,084)	260,187	-	(Note 11)
and trading	·	, ,										
Logistics management service	288,100	(Note 4)	-	-	-	-	(3,755)	81.23%	(3,755)	296,438	-	(Note 11)
Developing farming technology	88,173	(Note 3)	_	_	_	-	(25,768)	81.23%	(25,768)	51,034	-	(Note 11)
and trading	ŕ	,					, , ,		, , ,	ŕ		, ,
Developing hog farming technology	276,400	(Note 4)	221,120	-	-	221,120	(24,914)	81.23%	(24,914)	263,138	-	(Note 11)
	ŕ	,	ŕ			· ·	, , ,		, , ,	ŕ		, ,
Information software services	27,860	(Note 4)	27,860	-	-	27,860	(2,242)	81.23%	(2,242)	24,302	-	(Note 11)
Biotechnology testing service	111,560	(Note 4)	-	-	-	-	(2,083)	81.23%	(2,083)	106,483	-	(Note 11)
Biotech research and development and	27,680	(Note 1)	27,680	-	-	27,680	1,575	81.23%	1,575	31,107	-	(Note 11)
Selling of high density gene chip and testing service	18,275	(Note 2)	12,125	6,150	-	18,275	(3,446)	75.21%	(3,446)	4,340	-	(Note 11)
	Developing hog farming technology and trading Farm feed developing and trading Developing hog farming technology and trading Logistics management service Developing hog farming technology and trading Developing hog farming technology and trading Developing hog farming technology and trading Logistics management service Developing farming technology and trading Developing hog farming technology and trading Developing hog farming technology and trading Information software services Biotechnology testing service Biotech research and development and bioassay Selling of high density gene chip	Developing hog farming technology and trading Logistics management service Developing hog farming technology and trading Developing hog farming technology and trading Developing hog farming technology and trading Developing farming technology and trading Logistics management service Developing farming technology and trading Developing farming technology and trading Developing hog farming technology and trading Developing hog farming technology and trading Developing technology and trading Developing hog farming technology and trading Developing technology and trading Developing hog farming technology and trading Developing farming technology and trading Developing hog farming technology and trading an	Developing hog farming technology and trading Farm feed developing and trading Developing hog farming technology and trading Developing farming technology and trading t	Developing hog farming technology and trading 1,314,369 (Note 1) 3,309,022	Developing hog farming technology and trading Developing hog farming technology Developing hog f	Developing hog farming technology and trading Developing hog farming technology and trading Taiwanat the beginning of this year Outflow Inflow	Developing hog farming technology and trading 1,314,369 (Note 1) 1,291,505 - 3,309,022 and trading 1,314,369 (Note 1) 1,291,505 - 3,309,022 and trading 1,314,369 (Note 1) 1,291,505 - 1,291,505 Developing hog farming technology and trading 1,314,369 (Note 1) 1,221,874 - - 1,122,874 and trading 1,314,369 (Note 1) 1,122,874 - - 1,122,874 and trading 1,314,369 (Note 1) 1,122,874 - - 1,122,874 and trading 1,314,369 (Note 4) 651,142 - 651,142 and trading 1,314,369 (Note 4) 651,142 - 651,142 and trading 1,314,369 (Note 4) 651,142 - 651,142 and trading 1,314,369 (Note 4) 1,122,874 - - 651,142 and trading 1,314,369 (Note 1) 1,314,369 (Note 1)	Developing hog farming technology and trading 1,314,369 (Note 1) 1,221,874 3,309,022 (487,417)	Developing log farming technology and trading 1,314,369 (Note 1) 3,309,022 - 5,309,022 (487,417) 81,23% (169,288) 2,009,010 (Note 1) 1,291,505 - 1,291,505 (184,654) 81,23% (169,288) (1	Part	mod products mod products mode mode	Percelopating log farming sechnology and stronglish of the log spin sechnology and strong sechnology and sechno

(ii) Limitation on investment in mainland China:

(In thousands of Dollars)

Investor Company Name	Accumulated Investment in mainland Chi at the end (Note 8)(Note 9)	Investment Amounts Authorized by Investment Commission, MOEA	Upper Limit on Investment (Note 10)
The Company and subsidiaries	9,754,10	5 11,368,522	20,914,192
The Company and subsidiaries	(USD 331,189) (USD 352,294)	20,914,192

- Note 1: The Group invested in mainland China companies through Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd., which is established in a third region.
- Note 2: The Group invested in mainland China companies through Phalanx Biotech Limited, which is established in a third region.
- Note 3: The Company invested in mainland China companies through Jiansu Win Chance Agriculture Development Co., Ltd.
- Note 4: The Company invested in mainland China companies through Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.
- Note 5: The amount of net income (losses) was recognized based on the reviewed financial statements of the investee companies.
- Note 6: Carrying value as of September 30, 2023 was with reference to the amount recognized by the investment through subsidiaries to subsidiaries established in a third region.
- Note 7: Investment income (loss) recognized was translated into New Taiwan Dollars at the average exchange rate for the each month from January 1 to September 30, 2023.
- Note 8: The Group acquired Vanchip (Tianjin) Technology Co., Ltd. through a third region, wherein the outflow of investment from Taiwan amounted US\$9,383 thousand (NT\$261,420 thousand).
- Note 9: Jiansu Merit/Cofcojoycome Agriculture Development Co., Ltd. had been liquidated on January 25, 2019. However, according to the regulation of Investment Commission the remittance to mainland China amounting to US\$4,872 thousand (NT\$149,664 thousand) was included in the accumulated investment account.
- Note10: Amount of upper limit on investment was the higher between sixty percentage of total equity or total consolidated equity.
- Note11: The amount of the transaction and the ending balance had been offset in the consolidated financial statements.
 - (iii) Significant transactions: Please refer Schedule A, Schedule B, Schedule D, Schedule F, Schedule G and Schedule H.

Schedule K Information on major shareholders:

(In shares)

		(III shares)
Shareholding Shareholder's Name	Shares	Percentage
Cathay Life Insurance Co., Ltd.	21,598,000	5.09%